:: CLDF ::

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers

Contemp Clin Trials. 2020 Oct 8;106174. doi: 10.1016/j.cct.2020.106174. Online ahead of print.

Stephen A Harrison¹, Salvatore Calanna², Kenneth Cusi³, Martin Linder⁴, Takeshi Okanoue⁵, Vlad Ratziu⁶, Arun Sanyal⁷, Anne-Sophie Sejling⁸, Philip N Newsome⁹

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

J Hepatol. 2020 Oct 7;S0168-8278(20)33673-4. doi: 10.1016/j.jhep.2020.09.029.Online ahead of print.

Catherine Frenette¹, Zeid Kayali², Edward Mena³, Parvez S Mantry⁴, Kathryn J Lucas⁵, Guy Neff⁶, Miguel Rodriguez⁷, Paul J Thuluvath⁸, Ethan Weinberg⁹, Bal R Bhandari¹⁰, James Robinson¹¹, Nicole Wedick¹², Jean L Chan¹¹, David T Hagerty¹¹, Kris V Kowdley¹³, IDN-6556-17 Study Investigators

One Year

J Clin Med. 2020 Oct 6;9(10):E3213. doi: 10.3390/jcm9103213.

Louise Vedtofte^1 2, Emilie Bahne^1 2, Signe Foghsgaard^1 2 3, Jonatan I Bagger^1 2, Camilla Andreasen^1 2, Charlotte Strandberg⁴, Peter M Gørtz⁵, Jens J Holst^6 7, Henning Grønbæk⁸, Jens A Svare⁹, Tine D Clausen¹⁰, Elisabeth R Mathiesen^11 12, Peter Damm^12 13, Lise L Gluud^12 14, Filip K Knop^1 2 7 12, Tina Vilsbøll^1 2 12

The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

Contemp Clin Trials. 2020 Oct 9;106175. doi: 10.1016/j.cct.2020.106175. Online ahead of print.

Timothy Hardy¹, Kristy Wonders², Ramy Younes³, Guruprasad P Aithal⁴, Rocio Aller⁵, Michael Allison⁶, Pierre Bedossa², Fay Betsou⁷, Jerome Boursier⁸, M Julia Brosnan⁹, Alastair Burt¹, Jeremy Cobbold¹⁰, Helena Cortez-Pinto¹¹, Chris P Day¹, Jean-Francois Dufour¹², Mattias Ekstedt¹³, Sven Francque¹⁴, Stephen Harrison¹⁵, Luca Miele¹⁶, Patrik Nasr¹³, George Papatheodoridis¹⁷, Salvatore Petta¹⁸, Dina Tiniakos¹⁹, Richard Torstenson²⁰, Luca Valenti²¹, Adriaan G Holleboom²², Hannele Yki-Jarvinen²³, Andreas Geier²⁴, Manuel Romero-Gomez²⁵, Vlad Ratziu²⁶, Elisabetta Bugianesi²⁷, Jörn M Schattenberg²⁸, Quentin M Anstee²⁹, LITMUS Consortium

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

Gut. 2020 Oct 9;gutjnl-2020-322786. doi: 10.1136/gutjnl-2020-322786. Online ahead of print.

Tracey G Simon^1 2 3, Bjorn Roelstraete⁴, Hamed Khalili^1 2 3, Hannes Hagström⁵, Jonas F Ludvigsson^{6 7 8 9 10}

Testosterone is Associated With Nonalcoholic Steatohepatitis (NASH) and Fibrosis in Pre-Menopausal Women With NAFLD

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31375-6.doi: 10.1016/j.cgh.2020.09.045. Online ahead of print.

Monika Sarkar¹, Ayako Suzuki², Manal Abdelmalek², Katherine Yates³, Laura Wilson³, Nathan M Bass⁴, Ryan Gill², Marcelle Cedars⁵, Norah Terrault⁶, NASH Clinical Research Network (NASH CRN)

Non-Alcoholic Fatty Liver Disease in a sample of individuals with Bipolar Disorders: Results From the FACE-BD Cohort

Acta Psychiatr Scand. 2020 Oct 4. doi: 10.1111/acps.13239. Online ahead of print.

Ophelia Godin^1 2, Marion Leboyer^1 2, Raoul Belzeaux^1 3, Frank Bellivier^1 4, Joséphine Loftus^1 5, Philippe Courtet^1 6, Caroline Dubertret^1 7, Sebastien Gard^1 8, Chantal Henry⁹, Pierre-Michel Llorca^1 10, Raymund Schwan^1 11, Christine Passerieux^1 12, Mircea Polosan^1 13, Ludovic Samalin^1 10, Emilie Olié^1 6, Bruno Etain^1 4, FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators

Collaborators

FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators:

B Etain, C Henry, E Olié, M Leboyer, E Haffen, P M Llorca, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, H Mondor, S Hotier, A Pelletier, N Drancourt, J P Sanchez, E Saliou, C Hebbache, J Petrucci, L Willaume, E Bourdin, F Bellivier, M Carminati, B Etain, J Maruani, E Marlinge, M Meyrel, B Antoniol, A Desage, S Gard, A Jutant, K Mbailara, I Minois, L Zanouy, L Bardin, A Cazals, P Courtet, B Deffinis, D Ducasse, M Gachet, A Henrion, F Molière, B Noisette, E Olié, G Tarquini, R Belzeaux, N Correard, F Groppi, A Lefrere, L Lescalier, E Moreau, J Pastol, M Rebattu, B Roux, N Viglianese, R Cohen, Raymund Schwan, J P Kahn, M Milazzo, O Wajsbrot-Elgrabli, T Bougerol, B Fredembach, A Suisse, B Halili, A Pouchon, M Polosan, A M Galliot, I Grévin, A S Cannavo, N Kayser, C Passerieux, P Roux, V Aubin, I Cussac, M A Dupont, J Loftus, I Medecin, C Dubertret, N Mazer, C Portalier, C Scognamiglio, A Bing

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

Jeffrey Budd¹, Kenneth Cusi^2 3

Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease

Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

Ali Canbay¹, Nandita Kachru², Jennifer Scarlet Haas³, Jan-Peter Sowa¹, Dominic Meise³, Ahmet Burak Ozbay²

10.

Identifying High-Risk NASH Patients: What We Know so Far

Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473.eCollection 2020.

Marten Schulz¹, Frank Tacke¹

11.

Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease

BMJ Open. 2020 Sep 28;10(9):e040970. doi: 10.1136/bmjopen-2020-040970.

Theresa Hydes¹, Ryan Buchanan², Oliver J Kennedy², Simon Fraser², Julie Parkes², Paul Roderick²

12.

Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival

Public Health. 2020 Sep 26;187:165-171. doi: 10.1016/j.puhe.2020.07.017. Online ahead of print.

H Innes¹, J R Morling², E A Aspinall³, D J Goldberg³, S J Hutchinson³, I N Guha⁴

13.

Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data

Adv Ther. 2020 Oct 1.doi: 10.1007/s12325-020-01503-x. Online ahead of print.

Grit Andersen¹, Leona Plum-Mörschel², Paul D Hockings^3 4, Anni Morsing⁵, Mads S Palle⁶, Olivia Svolgaard⁵, Anne Flint⁷

14.

The pharmacological treatment of non-alcoholic fatty liver disease in children

Expert Rev Clin Pharmacol. 2020 Sep 26. doi: 10.1080/17512433.2020.1829468.Online ahead of print.

Annalisa Crudele¹, Nadia Panera¹, Maria Rita Braghini¹, Clara Balsano², Anna Alisi¹

15.

Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation and Death in NAFLD

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31374-4.doi:10.1016/j.cgh.2020.09.044. Online ahead of print.

Tolga Gidener¹, Omar T Ahmed¹, Joseph J Larson², Kristin C Mara², Terry M Therneau², Sudhakar K Venkatesh³, Richard L Ehman³, Meng Yin³, Alina M Allen⁴

16.

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec.

Wolf Peter Hofmann^1 2, Peter Buggisch^2 3, Lisa Schubert^1 4, Nektarios Dikopoulos⁵, Jeannette Schwenzer⁶, Marion Muche⁴, Gisela Felten⁷, Renate Heyne⁸, Patrick Ingiliz⁹, Anna Schmidt¹⁰, Kerstin Stein¹¹, Heiner Wedemeyer¹², Thomas Berg¹³, Johannes Wiegand¹³, Frank Lammert¹⁴, Stefan Zeuzem¹⁵, Jörn M Schattenberg^16 17

17.

A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis

Sci Rep. 2020 Sep 17;10(1):15308. doi: 10.1038/s41598-020-71995-8.

Andrea Dennis¹, Sofia Mouchti², Matt Kelly², Jonathan A Fallowfield³, Gideon Hirschfield⁴, Michael Pavlides⁵, Rajarshi Banerjee²

18.

Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease

J Clin Hypertens (Greenwich). 2020 Sep 17. doi: 10.1111/jch.13938. Online ahead of print.

Jillian Price¹, Carey Escheik^1 2, Ali Weinstein³, Patrice Winter^1 2, Lynn Gerber¹, Zobair Younossi^1 2

19.

A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?

Diabetes Obes Metab. 2020 Sep 18. doi: 10.1111/dom.14196. Online ahead of print.

Rebecca K Vincent^# 1, David M Williams^# 2, Marc Evans²

20.

Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows

Semin Liver Dis. 2020 Sep 9. doi: 10.1055/s-0040-1709491. Online ahead of print.

Ian A Rowe^1 2 3

21.

Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

Dig Dis Sci. 2020 Sep 7. doi: 10.1007/s10620-020-06588-6. Online ahead of print.

Gabrielle Ritaccio¹, Gianna Stoleru¹, Ameer Abutaleb², Raymond K Cross², Kirti Shetty², Sasan Sakiani², Uni Wong³

22.

A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD

Obesity (Silver Spring). 2020 Sep 6. doi: 10.1002/oby.22964. Online ahead of print.

Mary P Moore^# 1 2, Rory P Cunningham^# 1 2, Ryan J Dashek^1 3, Justine M Mucinski², R Scott Rector^1 2 4

23.

Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Clin Gastroenterol Hepatol. 2020 Aug 31;S1542-3565(20)31220-9.doi: 10.1016/j.cgh.2020.08.061. Online ahead of print.

Jonathan G Stine, Nagambika Munaganuru, Abbey Barnard, Jennifer L Wang, Kellee Kaulback, Curtis K Argo, Siddarth Singh, Kathryn J Fowler, Claude B Sirlin, Rohit Loomba

24.

Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers

J Clin Med Res. 2020 Aug;12(8):472-482. doi: 10.14740/jocmr3932. Epub 2020 Jul 22.

Ebenezer T Oni¹, Vincent Figueredo², Ehimen Aneni³, Emir Veladar⁴, John W McEvoy⁵, Michael J Blaha^5 6, Roger S Blumenthal⁵, Raquel D Conceicao⁷, Jose A M Carvalho⁷, Raul D Santos^7 8, Khurram Nasir⁹

25.

Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty

Gastrointest Endosc. 2020 Aug 27;S0016-5107(20)34733-7. doi:10.1016/j.gie.2020.08.023.Online ahead of print.

Kaveh Hajifathalian¹, Amit Mehta¹, Bryan Ang², Daniel Skaf², Shawn Shah¹, Monica Saumoy³, Qais Dawod¹, Enad Dawod², Alpana Shukla⁴, Louis Aronne⁴, Robert Brown¹, David Cohen¹, Andrew J Dannenberg⁵, Brett Fortune¹, Sonal Kumar¹, Reem Z Sharaiha⁶

26.

Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging

Alzheimers Dement (N Y). 2020 Aug 24;6(1):e12065.doi: 10.1002/trc2.12065. eCollection 2020.

Vincenzo Solfrizzi¹, Emanuele Scafato^2 3, Carlo Custodero¹, Francesca Loparco¹, Alessandro Ciavarella¹, Francesco Panza^4 5, Davide Seripa^4 6, Bruno Pietro Imbimbo⁷, Madia Lozupone⁸, Nicola Napoli¹, Giuseppina Piazzolla¹, Lucia Galluzzo³, Claudia Gandin², Marzia Baldereschi⁹, Antonio Di Carlo⁹, Domenico Inzitari^9 10, Alberto Pilotto^1 11, Carlo Sabbà¹, Italian Longitudinal Study on Aging Working Group

27.

Tackling NAFLD: Three Targeted Populations

Hepatology. 2020 Aug 31. doi: 10.1002/hep.31533. Online ahead of print.

Kara Wegermann¹, Ayako Suzuki^1 2, Alisha M Mavis³, Manal F Abdelmalek¹, Anna Mae Diehl¹, Cynthia A Moylan^1 2

28.

Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD

Front Endocrinol (Lausanne). 2020 Jul 31;11:505. doi: 10.3389/fendo.2020.00505.eCollection 2020.

Annelise M Poss¹, Scott A Summers¹

29.

NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes

J Diabetes Complications. 2020 Jul 17;107684. doi: 10.1016/j.jdiacomp.2020.107684.Online ahead of print.

Rosa Lombardi¹, Lorena Airaghi², Giovanni Targher³, Gaetano Serviddio⁴, Gabriele Maffi², Alessandro Mantovani³, Claudio Maffeis⁵, Antonio Colecchia⁶, Rosanna Villani⁴, Luca Rinaldi⁷, Emanuela Orsi⁸, Giuseppina Pisano², Luigi Elio Adinolfi⁷, Silvia Fargion², Anna Ludovica Fracanzani²

30.

Mechanisms of nonalcoholic fatty liver disease and implications for surgery

Langenbecks Arch Surg. 2020 Aug 24. doi: 10.1007/s00423-020-01965-1.Online ahead of print.

Benedikt Kaufmann^1 2, Agustina Reca¹, Baocai Wang², Helmut Friess², Ariel E Feldstein¹, Daniel Hartmann³

31.

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169.Epub 2020 Aug 4.

Tobias Boettler¹, Thomas Marjot², Philip N Newsome^3 4, Mario U Mondelli⁵, Mojca Maticic^6 7, Elisa Cordero⁸, Rajiv Jalan⁹, Richard Moreau^10 11, Markus Cornberg^12 13, Thomas Berg¹⁴

32.

Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program

PLoS One. 2020 Aug 25;15(8):e0237430.doi: 10.1371/journal.pone.0237430. eCollection 2020.

Marina Serper^1 2 3, Marijana Vujkovic¹, David E Kaplan^1 2, Rotonya M Carr^1 2, Kyung Min Lee^4 5 6, Qing Shao⁴, Donald R Miller⁴, Peter D Reaven⁷, Lawrence S Phillips^8 9, Christopher J O'Donnell^10 11, James B Meigs¹², Peter W F Wilson^8 9, Rachel Vickers-Smith¹³, Henry R Kranzler^13 14, Amy C Justice^15 16 17, John M Gaziano^10 18, Sumitra Muralidhar¹⁹, Saiju Pyarajan^10 11, Scott L DuVall^6 20, Themistocles L Assimes^21 22, Jennifer S Lee^21 22, Philip S Tsao^21 22, Daniel J Rader^{2 23 24 25}, Scott M Damrauer^1 26, Julie A Lynch^6 27, Danish Saleheen^1 28, Benjamin F Voight^1 23 29, Kyong-Mi Chang^1 2, VA Million Veteran Program

33.

History of Nonalcoholic Fatty Liver Disease

Int J Mol Sci. 2020 Aug 16;21(16):E5888. doi: 10.3390/ijms21165888.

Amedeo Lonardo¹, Simona Leoni², Khalid A Alswat³, Yasser Fouad⁴

34.

Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic

Hepatology. 2020 Aug 14;10.1002/hep.31522. doi: 10.1002/hep.31522. Online ahead of print.

Naim Alkhouri¹, Anita Kohli¹, Rohit Loomba², Stephen A Harrison³

35.

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis

Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523. Online ahead of print.

Rohit Loomba¹, Lei Ling², Duy M Dinh³, Alex M DePaoli², Hsiao D Lieu², Stephen A Harrison^4 5, Arun J Sanyal⁶

36.

Anti-inflammatory Activities of Green Tea Catechins along the Gut-liver Axis in Nonalcoholic Fatty Liver Disease: Lessons Learned from Preclinical and Human Studies

J Nutr Biochem. 2020 Aug 12;108478. doi: 10.1016/j.jnutbio.2020.108478.Online ahead of print.

Joanna K Hodges¹, Geoffrey Y Sasaki¹, Richard S Bruno²

37.

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes

J Hepatocell Carcinoma. 2020 Jul 30;7:107-116. doi: 10.2147/JHC.S252506.eCollection 2020.

Claudia Campani^# 1, Carolina Bensi^# 1, Stefano Milani¹, Andrea Galli¹, Mirko Tarocchi¹

38.

Racial and Socioeconomic Disparities in Hospitalization of Pediatrics with Liver Disease from 2005 to 2015

Dig Dis Sci. 2020 Aug 14. doi: 10.1007/s10620-020-06530-w. Online ahead of print.

Melissa Martin¹, Biyao Zou², Joseph Hoang², Donghak Jeong², Rachel Bensen¹, Mindie H Nguyen³

39.

Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes

Diabetes Metab. 2020 Aug 10;S1262-3636(20)30102-6. doi: 10.1016/j.diabet.2020.07.010.Online ahead of print.

Paola León-Mimila¹, Hugo Villamil-Ramírez², Xinmin S Li³, Diana M Shih¹, Simon T Hui¹, Elvira Ocampo-Medina², Blanca López-Contreras², Sofía Morán-Ramos⁴, Marisol Olivares-Arevalo², Paula Grandini-Rosales², Luis Macías-Kauffer², Israel González-González⁵, Rogelio Hernández-Pando⁶, Francisco Gómez-Pérez⁷, Francisco Campos-Pérez⁵, Carlos Aguilar-Salinas⁸, Elena Larrieta-Carrasco⁹, Teresa Villarreal-Molina¹⁰, Zeneng Wang³, Aldons J Lusis¹, Stanley L Hazen¹¹, Adriana Huertas-Vazquez¹², Samuel Canizales-Quinteros¹³

40.

Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy

Surg Obes Relat Dis. 2020 Jul 14;S1550-7289(20)30411-1. doi: 10.1016/j.soard.2020.07.009.Online ahead of print.

Sébastien Frey¹, Stéphanie Patouraux², Tarek Debs³, Jean Gugenheim⁴, Rodolphe Anty⁵, Antonio Iannelli⁶

41.

Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials

Cureus. 2020 Jul 6;12(7):e9018. doi: 10.7759/cureus.9018.

Muhammad Usman^1 2, Nabiyah Bakhtawar³

42.

NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment

Endocrinology. 2020 Aug 10;bqaa134.doi: 10.1210/endocr/bqaa134. Online ahead of print.

Johanna K DiStefano¹

43.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Gastroenterology. 2020 Aug 8;S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004.Online ahead of print.

Stephen A Harrison¹, Guy Neff², Cynthia D Guy³, Mustafa R Bashir⁴, Angelo H Paredes⁵, Juan P Frias⁶, Ziad Younes⁷, James F Trotter⁸, Nadege T Gunn⁹, Sam E Moussa¹⁰, Anita Kohli¹¹, Kristin Nelson¹², Mildred Gottwald¹², William C G Chang¹², Andrew Z Yan¹², Alex M DePaoli¹², Lei Ling¹³, Hsiao D Lieu¹²

44.

Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future

Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.

Sonja Lang¹, Bernd Schnabl²

45.

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Lancet Gastroenterol Hepatol. 2020 Aug 4;S2468-1253(20)30252-1.doi: 10.1016/S2468-1253(20)30252-1. Online ahead of print.

Stephen A Harrison¹, Vlad Ratziu², Jérôme Boursier³, Sven Francque⁴, Pierre Bedossa⁵, Zouher Majd⁶, Geneviève Cordonnier⁶, Fouad Ben Sudrik⁶, Raphael Darteil⁷, Roman Liebe⁸, Jérémy Magnanensi⁶, Yacine Hajji⁶, John Brozek⁶, Alice Roudot⁶, Bart Staels⁹, Dean W Hum⁶, Sophie Jeannin Megnien¹⁰, Suneil Hosmane⁶, Noémie Dam⁶, Pierre Chaumat⁶, Rémy Hanf¹¹, Quentin M Anstee¹², Arun J Sanyal¹³

46.

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities

Hepatol Commun. 2020 May 19;4(8):1136-1148. doi: 10.1002/hep4.1534. eCollection 2020 Aug.

Pegah Golabi¹, James M Paik¹, Tamoore Arshad², Youssef Younossi³, Alita Mishra², Zobair M Younossi^1 2

47.

The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development

Physiol. 2020 Jul 3;11:767. doi: 10.3389/fphys.2020.00767. eCollection 2020.

Rory P Cunningham^1 2, Ryan D Sheldon³, R Scott Rector^1 2 4

48.

Non-invasive diagnostic tools for pediatric NAFLD: where are we now?

Expert Rev Gastroenterol Hepatol. 2020 Jul 25.doi: 10.1080/17474124.2020.1801413.Online ahead of print.

Antonella Mosca¹, Nadia Panera², Annalisa Crudele², Anna Alisi²

49.

Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone

BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596.

Daniel Bradshaw¹, Yvonne Gilleece², Sumita Verma³, Iga Abramowicz³, Stephen Bremner³, Nicky Perry³

50.

A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study

Front Nutr. 2020 May 21;7:71. doi: 10.3389/fnut.2020.00071. eCollection 2020.

Sudipa Sarkar¹, Loren Lipworth^2 3, Edmond K Kabagambe^2 3, Aihua Bian^3 4, Thomas G Stewart⁴, William J Blot^2 5, T Alp Ikizler^3 6, Adriana M Hung^3 6

51.

Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study

Nutrients. 2020 Jul 18;12(7):E2141. doi: 10.3390/nu12072141.

Mikiko Watanabe¹, Renata Risi¹, Elisabetta Camajani¹, Savina Contini¹, Agnese Persichetti¹, Dario Tuccinardi², Ilaria Ernesti³, Stefania Mariani¹, Carla Lubrano¹, Alfredo Genco³, Giovanni Spera¹, Lucio Gnessi¹, Sabrina Basciani¹

52.

Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis

J Neuroimaging. 2020 Jul 23. doi: 10.1111/jon.12728. Online ahead of print.

Thao T Tran¹, Ke Wei¹, Soren Cole¹, Edward Mena², Marie Csete¹, Kevin S King¹

53.

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

J Hepatol. 2020 Jun 28;S0168-8278(20)30399-8. doi: 10.1016/j.jhep.2020.06.025.Online ahead of print.

Beth A Davison¹, Stephen A Harrison², Gad Cotter³, Naim Alkhouri⁴, Arun Sanyal⁵, Christopher Edwards³, Jerry R Colca⁶, Julie Iwashita⁶, Gary G Koch⁷, Howard C Dittrich⁶

54.

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis

Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.

Margery A Connelly¹, Jonathan Velez Rivera², John R Guyton², Mohammad Shadab Siddiqui³, Arun J Sanyal³

55.

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.

Theresa J Hydes¹, Sujan Ravi¹, Rohit Loomba², Meagan E Gray¹

56.

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases

Ethan M Weinberg¹, Huy N Trinh², Roberto J Firpi³, Kalyan Ram Bhamidimarri⁴, Samuel Klein⁵, Jonathan Durlam⁶, Stephanie Watkins⁶, K Rajender Reddy¹, Michael Weiss⁷, Richard C Zink⁶, Anna S Lok⁸

Clin Gastroenterol Hepatol. 2020 Jul 3;S1542-3565(20)30930-7. doi:10.1016/j.cgh.2020.06.066.Online ahead of print.

57.

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.

Zobair M Younossi¹, Kathleen E Corey², Naim Alkhouri³, Mazen Noureddin⁴, Ira Jacobson⁵, Brian Lam¹, Stephen Clement¹, Rita Basu⁶, Stuart Gordon⁷, Natarajan Ravendhra⁸, Puneet Puri⁹, Mary Rinella¹⁰, Peter Scudera¹, Ashwani K Singal¹¹, Linda Henry¹², US Members of the Global Nash Council

58.

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.

Laura Craven¹, Adam Rahman^2 3, Seema Nair Parvathy⁴, Melanie Beaton^2 3, Justin Silverman⁵, Karim Qumosani^2 3, Irene Hramiak^2 6, Rob Hegele^2 6 7, Tisha Joy^2 6, Jon Meddings⁸, Brad Urquhart², Ruth Harvie⁹, Charles McKenzie^2 7, Kelly Summers^1 2, Gregor Reid^1 2 9, Jeremy P Burton^1 2 9, Michael Silverman^1 2 4

59.

Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes

Diabet Med. 2020 Jul 3. doi: 10.1111/dme.14356. Online ahead of print.

T J Hydes¹, N Summers², E Brown^3 4, U Alam^3 4 5, H Thomaides-Brears⁶, J P H Wilding^3 4, D J Cuthbertson^3 4

60.

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Hepatol Int. 2020 Jul 4;1-11.doi: 10.1007/s12072-020-10072-8. Online ahead of print.

Shiv Kumar Sarin¹, Ashok Choudhury², George K Lau³, Ming-Hua Zheng^3 4, Dong Ji^3 5, Sherief Abd-Elsalam⁶, Jaeseok Hwang⁷, Xiaolong Qi⁸, Ian Homer Cua⁹, Jeong Ill Suh¹⁰, Jun Gi Park¹⁰, Opass Putcharoen¹¹, Apichat Kaewdech¹², Teerha Piratvisuth¹², Sombat Treeprasertsuk¹¹, Sooyoung Park¹³, Salisa Wejnaruemarn¹¹, Diana A Payawal¹⁴, Oidov Baatarkhuu¹⁵, Sang Hoon Ahn¹⁶, Chang Dong Yeo¹⁶, Uzziel Romar Alonzo¹⁴, Tserendorj Chinbayar¹⁷, Imelda M Loho¹⁸, Osamu Yokosuka¹⁹, Wasim Jafri²⁰, Soeksiam Tan²¹, Lau Ing Soo²¹, Tawesak Tanwandee²², Rino Gani²³, Lovkesh Anand²⁴, Eslam Saber Esmail⁶, Mai Khalaf⁶, Shahinul Alam²⁵, Chun-Yu Lin²⁶, Wan-Long Chuang²⁶, A S Soin²⁷, Hitendra K Garg²⁸, Kemal Kalista²⁹, Badamnachin Batsukh¹⁵, Hery Djagat Purnomo³⁰, Vijay Pal Dara³¹, Pravin Rathi³², Mamun Al Mahtab²⁵, Akash Shukla³³, Manoj K Sharma², Masao Omata^34 35, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)

61.

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease

J Clin Med. 2020 Jun 29;9(7):E2032. doi: 10.3390/jcm9072032.

Lauren A Newman¹, Michael J Sorich¹, Andrew Rowland¹

J Clin Med. 2020 Jun 29;9(7):E2032. doi: 10.3390/jcm9072032.

Lauren A Newman¹, Michael J Sorich¹, Andrew Rowland¹

62.

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score

Hepatol Commun.. 2020 May 26;4(7):998-1011. doi: 10.1002/hep4.1524. eCollection 2020 Jul.

Stuart C Gordon¹, Nandita Kachru², Emily Parker³, Stephanie Korrer³, A Burak Ozbay², Robert J Wong⁴

63.

Evolving Role for Pharmacotherapy in NAFLD/NASH

Clin Transl Sci. 2020 Jun 25. doi: 10.1111/cts.12839. Online ahead of print.

Suzanna L Attia¹, Samir Softic^1 2 3, Marialena Mouzaki⁴

64.

Nonalcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Nephrolithiasis in Women: Findings From NHANES III

J Endourol. 2020 Jun 22.doi: 10.1089/end.2020.0486. Online ahead of print.

Rourke Douglas Decker¹, Eric M Ghiraldi², Alexandra H Weiss³, John P Gaughan⁴, Justin I Friedlander^5 6

65.

Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis

Front Physiol. 2020 Jun 3;11:551. doi: 10.3389/fphys.2020.00551. eCollection 2020.

Geraldine F Clough¹, Andrew J Chipperfield², Marjola Thanaj², Eleonora Scorletti^1 3 4, Philip C Calder^1 3, Christopher D Byrne^1 3

66.

Cirrhosis in a Young Child Due to Fatty Liver; Importance of Early Screening: A Case Report and Review of the Literature

Am J Case Rep. 2020 Jun 25;21:e923250. doi: 10.12659/AJCR.923250.

Hamza Hassan Khan¹, Christine E Klingert^1 2, Sanjay Kumar^2 3, Hernando Lyons^2 3

67.

COVID-19 and Nonalcoholic Fatty Liver Disease: Two Intersecting Pandemics

Eur J Clin Invest. 2020 Jun 26;e13338. doi: 10.1111/eci.13338. Online ahead of print.

Piero Portincasa¹, Marcin Krawczyk^2 3, Wiktor Smyk⁴, Frank Lammert², Agostino Di Ciaula¹

68.

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Ann Pharmacother. 2020 Jun 22;1060028020935105. doi: 10.1177/1060028020935105.Online ahead of print.

John A Dougherty¹, Erenie Guirguis¹, Krisy-Ann Thornby¹

69.

Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

Gastroenterol Hepatol. 2020 Jun 9;S1542-3565(20)30775-8.doi: 10.1016/j.cgh.2020.05.064. Online ahead of print.

Zobair M Younossi¹, Maria Stepanova², Janus Ong³, Greg Trimble⁴, Saleh AlQahtani⁵, Issah Younossi², Aijaz Ahmed⁶, Andrei Racila⁷, Linda Henry²

70.

Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials

Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.

Stephen A Harrison¹, Vincent Wai-Sun Wong², Takeshi Okanoue³, Natalie Bzowej⁴, Raj Vuppalanchi⁵, Ziad Younes⁶, Anita Kohli⁷, Shiv Sarin⁸, Stephen H Caldwell⁹, Naim Alkhouri¹⁰, Mitchell L Shiffman¹¹, Marianne Camargo¹², Georgia Li¹², Kathryn Kersey¹², Catherine Jia¹², Yanni Zhu¹², C Stephen Djedjos¹², G Mani Subramanian¹², Robert P Myers¹², Nadege Gunn¹³, Aasim Sheikh¹⁴, Quentin M Anstee¹⁵, Manuel Romero-Gomez¹⁶, Michael Trauner¹⁷, Zachary Goodman¹⁸, Eric J Lawitz¹⁰, Zobair Younossi¹⁸, STELLAR-3 and STELLAR-4 Investigators

71.

Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record

Dig Dis Sci. 2020 Jun 13. doi: 10.1007/s10620-020-06388-y. Online ahead of print.

Christopher J Danford¹, Jennifer Y Lee², Ian A Strohbehn³, Kathleen E Corey³, Michelle Lai⁴

72.

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.

Zobair M Younossi^1 2, Mary E Rinella³, Arun Sanyal⁴, Stephen A Harrison⁵, Elizabeth Brunt⁶, Zachary Goodman^1 2, David E Cohen⁷, Rohit Loomba⁸

73.

Novel Antisense Inhibition of Diacylglycerol O-acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial

Lancet Gastroenterol Hepatol. 2020 Jun 15;S2468-1253(20)30186-2.doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.

Rohit Loomba¹, Erin Morgan², Lynnetta Watts², Shuting Xia², Lisa A Hannan², Richard S Geary², Brenda F Baker², Sanjay Bhanot²

74.

Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Youth

J Clin Endocrinol Metab. 2020 Jun 19;dgaa382. doi: 10.1210/clinem/dgaa382.Online ahead of print.

Ayesha Monga Kravetz^1 2, Todd Testerman³, Brittany Galuppo², Joerg Graf³, Bridget Pierpont², Stephan Siebel², Richard Feinn¹, Nicola Santoro^2 4

75.

Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of Obesity in Children of Predominantly Hispanic/Latino Ancestry by Causal Mediation Analysis

PLoS One. 2020 Jun 22;15(6):e0234985. doi: 10.1371/journal.pone.0234985. eCollection 2020.

Presley H Nichols¹, Yue Pan², Benjamin May³, Martina Pavlicova², John C Rausch^1 4, Ali A Mencin⁴, Vidhu V Thaker⁴

76.

Non-alcoholic Fatty Liver Disease in Pregnancy Is Associated With Adverse Maternal and Perinatal Outcomes

J Hepatol. 2020 Apr 15;S0168-8278(20)30215-4. doi: 10.1016/j.jhep.2020.03.049.Online ahead of print.

Monika Sarkar¹, Joshua Grab², Jennifer L Dodge³, Erica P Gunderson⁴, Jessica Rubin⁵, Roxanna A Irani⁶, Marcelle Cedars⁷, Norah Terrault⁸

77.

Use of Metabolic Syndrome Severity to Assess Treatment With Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis

Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131. Online ahead of print.

Matthew J Gurka¹, Jasmine A Mack¹, Xiaofei Chi¹, Mark D DeBoer²

78.

Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt¹, David Petroff², Valentin Blank^1 3, Albrecht Böhlig¹, Florian van Bömmel¹, Christian Wittekind⁴, Thomas Berg¹, Thomas Karlas¹, Johannes Wiegand¹

79.

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand?

Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1.eCollection 2020.

Shaheen Tomah^1 2, Naim Alkhouri³, Osama Hamdy^1 2

80.

Prediction of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Using Gut Microbiota-Based Approaches Compared With Simple Non-Invasive Tools

Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.

Sonja Lang^1 2, Fedja Farowski^3 4 5, Anna Martin¹, Hilmar Wisplinghoff^6 7 8, Maria J G T Vehreschild^3 4 5, Marcin Krawczyk^9 10, Angela Nowag^6 8, Anne Kretzschmar⁶, Claus Scholz⁶, Philipp Kasper¹, Christoph Roderburg¹¹, Frank Lammert⁹, Tobias Goeser¹, Hans-Michael Steffen¹, Münevver Demir^12 13

81.

Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai

Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.

Robert J Pattison¹, James Phillip Esteban², Tomoki Sempokuya³, Jakrin Kewcharoen¹, Sumodh Kalathil⁴, Scott K Kuwada⁵

82.

Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future

Semin Liver Dis. 2020 Jun 11. doi: 10.1055/s-0040-1713006. Online ahead of print.

Leon A Adams^1 2, Wah-Kheong Chan³

83.

Burden of Nonalcoholic Fatty Liver Disease in Canada, 2019-2030: A Modelling Study

CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print Apr-Jun 2020.

Mark G Swain¹, Alnoor Ramji¹, Keyur Patel¹, Giada Sebastiani¹, Abdel Aziz Shaheen¹, Edward Tam¹, Paul Marotta¹, Magdy Elkhashab¹, Harpreet S Bajaj¹, Chris Estes², Homie Razavi¹

84.

Utilization of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis

Hepatology. 2020 May 8.doi: 10.1002/hep.31309. Online ahead of print.

Erin Wolf¹, Nicole E Rich¹, Jorge A Marrero¹, Neehar Parikh², Amit G Singal¹

85.

Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies

Clin Exp Hepatol. May-Jun 2020;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy¹, Hemnishil K Marella¹, Yu Jiang², Surosree Ganguli³, Peter Snell¹, Pradeep S B Podila⁴, Benedict Maliakkal¹, Sanjaya K Satapathy⁵

86.

Advances in Non-Invasive Biomarkers for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long¹, Sanil Gandhi², Rohit Loomba³

87.

Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?

Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413. Online ahead of print.

Ruth M Pfeiffer¹, Yaron Rotman², Thomas R O'Brien¹

88.

Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World

Liver Int .2020 Jun 1. doi: 10.1111/liv.14548. Online ahead of print.

Su Lin¹, Jiaofeng Huang¹, Mingfang Wang¹, Rahul Kumar², Yuxiu Liu¹, Shiying Liu¹, Yinlian Wu¹, Xiaozhong Wang³, Yueyong Zhu¹

89.

Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour^1 2, Cyrielle Caussy^3 4, Rohit Loomba⁵

90.

Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis

Aliment Pharmacol Ther. 2020 Jun;51(12):1305-1320. doi: 10.1111/apt.15738.Epub 2020 May 7.

Björn Carlsson¹, Daniel Lindén^1 2, Gabriella Brolén³, Mathias Liljeblad¹, Mikael Bjursell¹, Stefano Romeo^4 5 6, Rohit Loomba⁷

91.

Increased Atherogenic Lipoprotein Profile in Children With Non-Alcoholic Steatohepatitis

Pediatr Obes. 2020 May 4;e12648 doi: 10.1111/ijpo.12648. Online ahead of print.

Eduardo Castillo-Leon¹, Margery A Connelly², Juna V Konomi¹, Shelley Caltharp^3 4, Rebecca Cleeton¹, Miriam B Vos^1 4 5

92.

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease Are Major Drivers of Liver Mortality in the United States

Hepatol Commun. 2020 Apr 4;4(6):890-903. doi: 10.1002/hep4.1510. eCollection 2020 Jun.

James M Paik¹, Pegah Golabi¹, Rakesh Biswas¹, Saleh Alqahtani², Chapy Venkatesan¹, Zobair M Younossi^1 3

93.

Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality

Am J Gastroenterol. 2020 Jun 3. doi: 10.14309/ajg.0000000000000654. Online ahead of print.

Donghee Kim¹, Luis Miguel Vazquez-Montesino², Jessica A Escober¹, Christopher T Fernandes¹, George Cholankeril¹, Rohit Loomba^3 4, Stephen A Harrison^5 6, Zobair M Younossi⁷, Aijaz Ahmed¹

94.

Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt¹, David Petroff², Valentin Blank^1 3, Albrecht Böhlig¹, Florian van Bömmel¹, Christian Wittekind⁴, Thomas Berg¹, Thomas Karlas¹, Johannes Wiegand¹

95.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9.doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass¹, Claudia Filozof², Mazen Noureddin³, Mark Berner-Hansen⁴, Elmer Schabel⁵, Stephanie O Omokaro⁶, Jörn M Schattenberg⁷, Katherine Barradas⁸, Veronica Miller⁸, Sven Francque⁹, Manal F Abdelmalek¹⁰, Liver Forum Standard of Care Working Group

96.

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Gastroenterol. 2020 May 15. doi: 10.14309/ajg.0000000000000661. Online ahead of print.

97.

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.

Ramy Younes^1 2, Olivier Govaere², Salvatore Petta³, Luca Miele^4 5, Dina Tiniakos², Alastair Burt², Ezio David⁶, Fabio M Vecchio^4 7, Marco Maggioni⁸, Daniela Cabibi⁹, Anna L Fracanzani¹⁰, Chiara Rosso¹, Maria J Garcia Blanco¹¹, Angelo Armandi¹, Gian Paolo Caviglia¹, Marco Y W Zaki^2 12, Antonio Liguori⁴, Paolo Francione¹⁰, Grazia Pennisi³, Antonio Grieco^4 5, Luca Valenti¹³, Quentin M Anstee^2 14, Elisabetta Bugianesi¹

98.

Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data

Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.

Rohit Loomba^1 2, Robert Wong³, Jeremy Fraysse⁴, Sanatan Shreay⁴, Suying Li⁵, Stephen Harrison⁶, Stuart C Gordon⁷

99.

Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis

Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.

Kimberly P Newton^1 2, Joel E Lavine³, Laura Wilson^4 5, Cynthia Behling^6 7, Miriam B Vos⁸, Jean P Molleston⁹, Philip Rosenthal¹⁰, Tamir Miloh¹¹, Mark H Fishbein¹², Ajay K Jain¹³, Karen F Murray¹⁴, Jeffrey B Schwimmer^1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN):

Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates

100.

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo¹, Ayako Suzuki²

101.

Evolving Aspects of Liver Transplantation for Nonalcoholic Steatohepatitis

Curr Opin Organ Transplant. 2013 Jun;18(3):251-8.doi: 10.1097/MOT.0b013e3283615d30.

Michael Charlton¹

102.

Non-alcoholic Liver Disease and Childhood Obesity

Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.

Meera Shaunak¹, Christopher D Byrne^2 3, Nikki Davis^1 2, Paul Afolabi^2 3, Saul N Faust^2 3 4, Justin Huw Davies^5 2

103.

Decompensated Cirrhosis Is the Commonest Presentation for NAFLD Patients Undergoing Liver Transplant Assessment

Clin Med (Lond). 2020 May;20(3):313-318. doi: 10.7861/clinmed.2019-0250.

Ahmed Hussain¹, Preya J Patel¹, Freya Rhodes¹, Ankur Srivastava¹, David Patch¹, William Rosenberg²

104.

Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study

MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.

Abdel Aziz Shaheen¹, Kiarash Riazi², Alexandra Medellin², Deepak Bhayana², Gilaad G Kaplan², Jason Jiang², Roy Park², Wendy Schaufert², Kelly W Burak², Monica Sargious², Mark G Swain²

105.

The Effect of Sleep on Gastrointestinal Functioning in Common Digestive Diseases

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):616-624.doi: 10.1016/S2468-1253(19)30412-1.

William C Orr¹, Ronnie Fass², Shikha S Sundaram³, Ann O Scheimann⁴

106.

Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis

Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.

Fateh Bazerbachi¹, Eric J Vargas², Monika Rizk², Daniel B Maselli², Taofic Mounajjed³, Sudhakar K Venkatesh⁴, Kymberly D Watt², John D Port⁴, Rita Basu⁵, Andres Acosta², Ibrahim Hanouneh², Naveen Gara⁶, Meera Shah⁷, Manpreet Mundi⁷, Matthew Clark⁷, Karen Grothe⁷, Andrew C Storm², Michael J Levy², Barham K Abu Dayyeh⁸

107.

Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis

Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.

Jason S Seidman¹, Ty D Troutman², Mashito Sakai¹, Anita Gola³, Nathanael J Spann¹, Hunter Bennett¹, Cassi M Bruni¹, Zhengyu Ouyang¹, Rick Z Li¹, Xiaoli Sun⁴, BaoChau T Vu¹, Martina P Pasillas¹, Kaori M Ego¹, David Gosselin⁵, Verena M Link⁶, Ling-Wa Chong⁷, Ronald M Evans⁸, Bonne M Thompson⁹, Jeffrey G McDonald⁹, Mojgan Hosseini¹⁰, Joseph L Witztum⁴, Ronald N Germain³, Christopher K Glass¹¹

108.

Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour^1 2, Cyrielle Caussy^3 4, Rohit Loomba⁵

109.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

110.

Antitumour Necrosis Factor-a Agents and Development of New-Onset Cirrhosis or Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort

BMJ Open Gastroenterol. 2020 Apr 15;7(1):e000349.doi: 10.1136/bmjgast-2019-000349.eCollection 2020.

Kuo-Tung Tang^1 2 3, Jean-François Dufour^4 5, Po-Hung Chen⁶, Ruben Hernaez^7 8, Susan Hutfless⁶

111.

Biomarkers of NAFLD and NASH

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long¹, Sanil Gandhi², Rohit Loomba³

112.

Macrophages in Metabolic Associated Fatty Liver Disease

World J Gastroenterol. 2020 Apr 28;26(16):1861-1878.doi: 10.3748/wjg.v26.i16.1861.

Jawaher Alharthi¹, Olivier Latchoumanin¹, Jacob George¹, Mohammed Eslam²

113.

Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies

J Clin Exp Hepatol. May-Jun 2020;10(3):245-254.doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy¹, Hemnishil K Marella¹, Yu Jiang², Surosree Ganguli³, Peter Snell¹, Pradeep S B Podila⁴, Benedict Maliakkal¹, Sanjaya K Satapathy⁵

114.

Blood Lead Level Is Associated With Advanced Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Survey (NHANES 2011-2016)

Ann Hepatol. 2020 Apr 4;S1665-2681(20)30028-4. doi: 10.1016/j.aohep.2020.03.006.Online ahead of print.

Debashis Reja¹, Aayush Visaria², Briette Karanfilian³, Vinod Rustgi⁴

115.

Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis

Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15738. Online ahead of print.

Björn Carlsson¹, Daniel Lindén^1 2, Gabriella Brolén³, Mathias Liljeblad¹, Mikael Bjursell¹, Stefano Romeo^4 5 6, Rohit Loomba⁷

116.

Epidemiology and Pathophysiology of the Association Between NAFLD and Metabolically Healthy or Metabolically Unhealthy Obesity

Ann Hepatol. 2020 Mar 21;S1665-2681(20)30023-5.doi: 10.1016/j.aohep.2020.03.001. Online ahead of print.

Amedeo Lonardo¹, Alessandro Mantovani², Simonetta Lugari³, Giovanni Targher²

117.

The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study

Clin Transl Gastroenterol. 2020 Apr;11(4):e00170. doi: 10.14309/ctg.0000000000000170.

Carmen S S Latenstein¹, Louise J M Alferink², Sarwa Darwish Murad², Joost P H Drenth³, Cornelis J H M van Laarhoven¹, Philip R de Reuver¹

118.

Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data

Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15679. Online ahead of print.

Rohit Loomba^1 2, Robert Wong³, Jeremy Fraysse⁴, Sanatan Shreay⁴, Suying Li⁵, Stephen Harrison⁶, Stuart C Gordon⁷

119.

Nutrition and Genetics in NAFLD: The Perfect Binomium

Int J Mol Sci. 2020 Apr 23;21(8):E2986. doi: 10.3390/ijms21082986.

Marica Meroni^1 2, Miriam Longo^1 3, Alice Rustichelli¹, Paola Dongiovanni¹

120.

Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease

Curr Pharm Des. 2020 Apr 28.doi: 10.2174/1381612826666200429093648.Online ahead of print.

Francesco Tovoli¹, Silvia Ferri², Fabio Piscaglia¹

121.

Thyroid Hormone Signaling and the Liver

Hepatology. 2020 Apr 28.doi: 10.1002/hep.31296. Online ahead of print.

Megan J Ritter¹, Izuki Amano^1 2, Anthony N Hollenberg¹

122.

Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner^1 2, Tamoore Arshad¹, Pegah Golabi², James Paik², Freba Farhat¹, Zobair M Younossi^3 4

123.

How Good Are Controlled Attenuation Parameter Scores From Fibroscan to Assess Steatosis, NASH, and Fibrosis?

Dig Dis Sci. 2020 Apr 27.doi: 10.1007/s10620-020-06269-4. Online ahead of print.

Joshua Trowell¹, Joseph Alukal¹, Talan Zhang¹, Li Liu², Anurag Maheshwari^1 3, Hwan Y Yoo¹, Paul J Thuluvath^4 5

124.

Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach

Metabolites. 2020 Apr 24;10(4):E168. doi: 10.3390/metabo10040168.

George N Ioannou^1 2 3, G A Nagana Gowda⁴, Danijel Djukovic⁴, Daniel Raftery^4 5 6

125.

Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner^1 2, Tamoore Arshad¹, Pegah Golabi², James Paik², Freba Farhat¹, Zobair M Younossi^3 4

126.

Is Bariatric Surgery Resolving NAFLD via Microbiota-Mediated Bile Acid Ratio Reversal? A Comprehensive Review

Surg Obes Relat Dis. 2020 Mar 20;S1550-7289(20)30131-3. doi: 10.1016/j.soard.2020.03.013.Online ahead of print.

Eider Talavera-Urquijo¹, Marc Beisani², José M Balibrea³, John C Alverdy⁴

127.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

128.

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

J Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo¹, Ayako Suzuki²

129.

Metabolic Risk Factors and Incident Advanced Liver Disease in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Population-Based Observational Studies

Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100.eCollection 2020 Apr.

Helen Jarvis¹, Dawn Craig¹, Robert Barker¹, Gemma Spiers¹, Daniel Stow¹, Quentin M Anstee^2 3, Barbara Hanratty¹

130.

African Americans Have a Distinct Clinical and Histologic Profile With Lower Prevalence of NASH and Advanced Fibrosis Relative to Caucasians

Eur J Gastroenterol Hepatol. 2020 Apr 20. doi: 10.1097/MEG.0000000000001735.Online ahead of print.

Sanjaya K Satapathy^1 2, Hemnishil K Marella³, Rajiv P Heda³, Surosree Ganguli⁴, Yala Kirthi Reddy⁵, Pradeep S B Podila¹, Ian Clark⁶, Benedict Maliakkal¹

131.

Potential Implications of COVID-19 in Non-Alcoholic Fatty Liver Disease

Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. Online ahead of print.

Grietje H Prins¹, Peter Olinga¹

132.

Obesity as a Risk Factor for Greater Severity of COVID-19 in Patients With Metabolic Associated Fatty Liver Disease

Metabolism. 2020 Apr 19;154244. doi: 10.1016/j.metabol.2020.154244. Online ahead of print.

Kenneth I Zheng¹, Feng Gao², Xiao-Bo Wang³, Qing-Feng Sun⁴, Ke-Hua Pan⁵, Ting-Yao Wang⁶, Hong-Lei Ma¹, Wen-Yue Liu⁷, Jacob George⁸, Ming-Hua Zheng⁹

133.	FXR Agonists as Therapy for Liver Disease
	Hoofnagle JH¹. Hepatology. 2020 Apr 10. doi: 10.1002/hep.31265. [Epub ahead of print]

134.	Obeticholic acid for the treatment of nonalcoholic steatohepatitis
	Shah RA¹, Kowdley KV¹. Expert Rev Gastroenterol Hepatol. 2020 Apr 3. doi: 10.1080/17474124.2020.1748498. [Epub ahead of print]

135.	Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease
	Adams LA^1,2, Wang Z^1,2, Liddle C³, Melton PE^4,5, Ariff A⁴, Chandraratna H⁶, Tan J⁷, Ching H¹, Coulter S³, de Boer B⁸, Christophersen CT^9,10, O'Sullivan TA⁹, Morrison M¹¹, Jeffrey GP^1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]

136.	Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study
	Watzinger C¹, Nonnenmacher T², Grafetstätter M¹, Sowah SA^1,3, Ulrich CM⁴, Kauczor HU², Kaaks R¹, Schübel R^1,2, Nattenmüller J², Kühn T¹. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.

137.	Relationship between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease in Persons with HIV
	Kaplan A^1,2, Simon TG², Henson JB², Wang T², Zheng H³, Osganian SA², Rosenblatt R¹, Lake J⁴, Corey KE². J Acquir Immune Defic Syndr. 2020 Mar 31. doi: 10.1097/QAI.0000000000002359. [Epub ahead of print]

138.	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
	Newsome PN¹, Palmer M², Freilich B³, Sheikh MY⁴, Sheikh A⁵, Sarles H⁶, Herring R⁷, Mantry P⁸, Kayali Z⁹, Hassanein T¹⁰, Lee HM², Aithal GP¹¹; Volixibat in Adults study group. J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186-0. doi: 10.1016/j.jhep.2020.03.024. [Epub ahead of print]

139.	Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma
	Neuman MG Prof¹, Cohen LB Dr², Malnick S Dr³. Chem Biol Interact. 2020 Mar 23;323:109054. doi: 10.1016/j.cbi.2020.109054. [Epub ahead of print]

140.	Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons
	Jorge JM¹, Golas A¹, Patel N¹, Gonzalvo JP¹, Murr MM². Surg Obes Relat Dis. 2020 Feb 5. pii: S1550-7289(20)30049-6. doi: 10.1016/j.soard.2020.01.028. [Epub ahead of print]

141.	Influence of adiposity, insulin resistance and intrahepatic triglyceride content on insulin kinetics
	Smith GI¹, Polidori DC², Yoshino M¹, Kearney ML¹, Patterson BW¹, Mittendorfer B¹, Klein S¹. J Clin Invest. 2020 Mar 19. pii: 136756. doi: 10.1172/JCI136756. [Epub ahead of print]

142.	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
	Goldner D¹, Lavine JE². Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048. [Epub ahead of print]

143.	Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It
	Traish AM¹. World J Mens Health. 2020 Mar 20. doi: 10.5534/wjmh.200012. [Epub ahead of print]

144.	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
	Cook N¹, Geier A², Schmid A³, Hirschfield G⁴, Kautz A⁵, Schattenberg JM⁶, Balp MM¹. JHEP Rep. 2020 Feb 1;2(2):100081. doi: 10.1016/j.jhepr.2020.100081. eCollection 2020 Apr.

145.	Nonalcoholic Steatohepatitis: A Review
	Sheka AC¹, Adeyi O², Thompson J³, Hameed B⁴, Crawford PA⁵, Ikramuddin S¹. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.

146.	Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
	Kang MK, Kim KO, Kim MC, Park JG, Jang BI. Dig Dis. 2020 Mar 5. doi: 10.1159/000506938. [Epub ahead of print]

147.	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk
	Han E¹, Lee YH^2,3, Kim YD⁴, Kim BK^2,5,6, Park JY^2,5,6, Kim DY^2,5,6, Ahn SH^2,5,6, Lee BW^2,3, Kang ES^2,3, Cha BS^2,3, Han KH^2,5,6, Nam HS⁴, Heo JH⁴, Kim SU^2,5,6. Am J Gastroenterol. 2020 Mar 3. doi: 10.14309/ajg.0000000000000572. [Epub ahead of print]

148.	Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
	Parry SA¹, Hodson L^2,3. Adv Ther. 2020 Mar 7. doi: 10.1007/s12325-020-01281-6. [Epub ahead of print]

149.	Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
	Pan CS¹, Stanley TL^1,2. Front Endocrinol (Lausanne). 2020 Feb 21;11:70. doi: 10.3389/fendo.2020.00070. eCollection 2020.

150.	Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease
	Ahmed HS^1,2, Pedersen N³, Jayanna MB^3,4, Ten Eyck P⁵, Sanchez A³, Murali AR^3,6. J Gen Intern Med. 2020 Mar 10. doi: 10.1007/s11606-020-05725-1. [Epub ahead of print]

151.

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

Harrison SA¹, Wai-Sun Wong V², Okanoue T³, Bzowej N⁴, Vuppalanchi R⁵, Younes Z⁶, Kohli A⁷, Sarin S⁸, Caldwell SH⁹, Alkhouri N¹⁰, Shiffman ML¹¹, Camargo M¹², Li G¹², Kersey K¹², Jia C¹², Zhu Y¹², Djedjos CS¹², Subramanian GM¹², Myers RP¹², Gunn N¹³, Sheikh A¹⁴, Anstee QM¹⁵, Romero-Gomez M¹⁶, Trauner M¹⁷, Goodman Z¹⁸, Lawitz EJ¹⁰, Younossi Z¹⁸; STELLAR-3 and STELLAR-4 Investigators. J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126-4. doi: 10.1016/j.jhep.2020.02.027. [Epub ahead of print]

152.

Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

Patel K¹, Harrison SA², Elkashab M³, Trotter JF⁴, Herring R⁵, Rojter S⁶, Kayali Z⁷, Wong VW⁸, Greenbloom S⁹, Jayakumar S¹⁰, Shiffman ML¹¹, Freilich B¹², Lawitz EJ, Gane E^13,14, Harting E¹⁵, Xu J¹⁵, Billin AN¹⁵, Chung C¹⁵, Djedjos CS¹⁵, Subramanian GM¹⁵, Myers RP¹⁵, Middleton MS¹⁰, Rinella M¹⁶, Noureddin M¹⁷. Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]

153.	Thyroid hormones and thyromimetics: A new approach to NASH?
	Sinha RA¹, Bruinstroop E², Singh BK³, Yen PM³. Hepatology. 2020 Feb 27. doi: 10.1002/hep.31204. [Epub ahead of print]

154.	Epidemiology of Non-alcoholic Fatty Liver Disease in North America
	Arshad T¹, Golabi P², Henry L³, Younossi ZM¹. Curr Pharm Des. 2020 Mar 2. doi: 10.2174/1381612826666200303114934. [Epub ahead of print]

155.	Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice
	El Sherif O¹, Dhaliwal A^1,2, Newsome PN^1,2,3, Armstrong MJ^1,2,3. Expert Rev Gastroenterol Hepatol. 2020 Feb 23:1-9. doi: 10.1080/17474124.2020.1731303. [Epub ahead of print]

156.	Advances in non-invasive assessment of hepatic fibrosis
	Loomba R¹, Adams LA². Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593. [Epub ahead of print]

157.	A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic LiverDisease Mainly Due to NAFLD
	Dong TS¹, Katzka W^1,2, Lagishetty V^1,2, Luu K^1,2, Hauer M^1,2, Pisegna J³, Jacobs JP^4,5,6. Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.

158.	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study
	VanWagner LB^1,2, Wilcox JE^2,3, Ning H², Lewis CE⁴, Carr JJ⁵, Rinella ME¹, Shah SJ³, Lima JAC⁶, Lloyd-Jones DM^2,3. J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279. Epub 2020 Feb 6.

159.	Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease
	Azzu V¹, Vacca M², Virtue S², Allison M³, Vidal-Puig A⁴. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30224-9. doi: 10.1053/j.gastro.2019.12.054.

160.	Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease
	Saran AR¹, Dave S¹, Zarrinpar A². Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30221-3. doi: 10.1053/j.gastro.2020.01.050.

161.

A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

Cusi K^1,2. Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

162.	New drugs for non-alcoholic steatohepatitis
	Cardoso AC^1,2, de Figueiredo-Mendes C³, A Villela-Nogueira C^1,2, Sanyal AJ⁴. Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.

163.	New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?
	Guaraldi G¹, Maurice JB², Marzolini C³, Monteith K⁴, Milic J¹, Tsochatzis E⁵, Bhagani S⁶, Morse CG⁷, Price JC⁸, Ingiliz P^9,10, Lemoine M¹¹, Sebastiani G¹²; SHIVER Network. Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177. [Epub ahead of print]

164.	The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
	Asfari MM^1,2, Talal Sarmini M², Alomari M², Lopez R³, Dasarathy S^4,5,6, McCullough AJ^4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]

165.	MAFLD: A consensus-driven proposed nomenclature for metabolic associated fattyliver disease
	Eslam M¹, Sanyal AJ², George J³; an international consensus panel. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312. [Epub ahead of print]

166.	Nonalcoholic fatty liver disease burden: Australia, 2019-2030
	Adams LA¹, Roberts SK², Strasser SI³, Mahady SE^4,5, Powell E⁶, Estes C⁷, Razavi H⁷, George J⁸. J Gastroenterol Hepatol. 2020 Feb 11. doi: 10.1111/jgh.15009. [Epub ahead of print]

167.	NAFLD as a driver of chronic kidney disease
	Byrne CD¹, Targher G². J Hepatol. 2020 Feb 11. pii: S0168-8278(20)30030-1. doi: 10.1016/j.jhep.2020.01.013. [Epub ahead of print]

168.	NAFLD 2020: The State of the Disease
	Cotter TG¹, Rinella M². Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052. [Epub ahead of print]

169.	Therapeutic landscape for NAFLD in 2020
	Neuschwander-Tetri BA¹. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30222-5. doi: 10.1053/j.gastro.2020.01.051. [Epub ahead of print]

170.	Natural history of NASH and HCC
	Negro F¹. Liver Int. 2020 Feb;40 Suppl 1:72-76. doi: 10.1111/liv.14362.

171.	Mechanisms of Fibrosis Development in NASH
	Schwabe RF¹, Tabas I², Pajvani UB³. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30169-4. doi: 10.1053/j.gastro.2019.11.311. [Epub ahead of print]

172.	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant
	Chandrakumaran A¹, Siddiqui MS². Gastroenterol Clin North Am. 2020 Mar;49(1):165-178. doi: 10.1016/j.gtc.2019.09.005.

173.	Burden of Disease due to Nonalcoholic Fatty Liver Disease
	Muthiah MD¹, Sanyal AJ². Gastroenterol Clin North Am. 2020 Mar;49(1):1-23. doi: 10.1016/j.gtc.2019.09.007.

174.	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
	Wattacheril J¹. Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. doi: 10.1016/j.gtc.2019.10.002. Epub 2019 Dec 24.

175.	Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD
	Hari A¹, Fealy CE², Axelrod CL³, Haus JM⁴, Flask CA¹, McCullough AJ⁵, Kirwan JP^1,3. Med Sci Sports Exerc. 2020 Feb 5. doi: 10.1249/MSS.0000000000002273. [Epub ahead of print]

176.	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
	Kozlitina J¹. Gastroenterol Clin North Am. 2020 Mar;49(1):25-44. doi: 10.1016/j.gtc.2019.09.001

177.	Is NAFLD Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart
	Henson JB¹, Roden M^2,3,4, Targher G⁵, Corey KE⁶. Hepatology. 2020 Feb 3. doi: 10.1002/hep.31156. [Epub ahead of print]

178.	Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
	Budd J¹, Cusi K². Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007. [Epub ahead of print]

179.	Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review
	Tariq R¹, Axley P², Singal AK³. J Clin Exp Hepatol. 2020 Jan-Feb;10(1):81-87. doi: 10.1016/j.jceh.2019.07.008. Epub 2019 Jul 25.

180.

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Taylor RS¹, Taylor RJ², Bayliss S³, Hagstrom H⁴, Nasr P⁵, Schattenberg JM⁶, Ishigami M⁷, Toyoda H⁸, Wai-Sun Wong V⁹, Peleg N¹⁰, Shlomai A¹¹, Sebastiani G¹², Seko Y¹³, Bhala N¹⁴, Younossi ZM¹⁵, Anstee QM¹⁶, McPherson S¹⁷, Newsome PN¹⁸; Collaborators. Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]

181.	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
	Yan T¹, Yan N², Wang P^1,3, Xia Y^1,4, Hao H², Wang G², Gonzalez FJ¹. Acta Pharm Sin B. 2020 Jan;10(1):3-18. doi: 10.1016/j.apsb.2019.11.017. Epub 2019 Dec 10.

182.	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis
	Henry ZH¹, Argo CK². Gastroenterol Clin North Am. 2020 Mar;49(1):45-62. doi: 10.1016/j.gtc.2019.09.002. Epub 2019 Dec 24.

183.	Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
	Ratziu V¹, Sanyal A², Harrison SA³, Wong VW⁴, Francque S⁵, Goodman Z⁶, Aithal GP⁷, Kowdley KV⁸, Seyedkazemi S⁹, Fischer L⁹, Loomba R^10,11, Abdelmalek MF¹², Tacke F^13,14. Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]

184.	Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis
	Loomba R¹, Neuschwander-Tetri BA², Sanyal A³, Chalasani N⁴, Diehl AM⁵, Terrault N⁶, Kowdley K⁷, Dasarathy S⁸, Kleiner D⁹, Behling C¹, Lavine J¹⁰, Van Natta M¹¹, Middleton M¹, Tonascia J¹¹, Sirlin C¹; NASH Clinical Research Network. Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]

185.	Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965
	Shirazi F¹, Wang J¹, Wong RJ². J Clin Exp Hepatol. 2020 Jan-Feb;10(1):30-36. doi: 10.1016/j.jceh.2019.06.007. Epub 2019 Jul 10.

186.	Multiparametric Magnetic Resonance Elastography Improves the Detection of NASHRegression Following Bariatric Surgery
	Allen AM¹, Shah VH¹, Therneau TM², Venkatesh SK³, Mounajjed T⁴, Larson JJ², Mara KC², Kellogg TA⁵, Kendrick ML⁵, McKenzie TJ⁵, Greiner SM¹, Li J³, Glaser KJ³, Wells ML³, Gunneson TJ⁶, Ehman RL³, Yin M³. Hepatol Commun. 2019 Nov 5;4(2):185-192. doi: 10.1002/hep4.1446. eCollection 2020 Feb.

187.

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Newsome PN¹, Sasso M², Deeks JJ³, Paredes A⁴, Boursier J⁵, Chan WK⁶, Yilmaz Y⁷, Czernichow S⁸, Zheng MH⁹, Wong VW¹⁰, Allison M¹¹, Tsochatzis E¹², Anstee QM¹³, Sheridan DA¹⁴, Eddowes PJ¹⁵, Guha IN¹⁵, Cobbold JF¹⁶, Paradis V¹⁷, Bedossa P¹⁸, Miette V², Fournier-Poizat C¹⁹, Sandrin L², Harrison SA²⁰. Lancet Gastroenterol Hepatol. 2020 Feb 3. pii: S2468-1253(19)30383-8. doi: 10.1016/S2468-1253(19)30383-8. [Epub ahead of print]

188.	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
	Esteban JPG¹, Asgharpour A². Gastroenterol Clin North Am. 2020 Mar;49(1):105-121. doi: 10.1016/j.gtc.2019.10.003.

189.	Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
	Tanwar S¹, Rhodes F¹, Srivastava A¹, Trembling PM¹, Rosenberg WM¹. World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109.

190.	Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis
	Ma X¹, Liu S^2,3, Zhang J¹, Dong M¹, Wang Y¹, Wang M¹, Xin Y^4,5. BMC Gastroenterol. 2020 Jan 14;20(1):10. doi: 10.1186/s12876-020-1165-z.

191.	Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
	Ritchie M¹, Hanouneh IA^1,2, Noureddin M³, Rolph T⁴, Alkhouri N⁵. Expert Opin Investig Drugs. 2020 Feb;29(2):197-204. doi: 10.1080/13543784.2020.1718104. Epub 2020 Jan 22.

192.

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Scorletti E¹, Afolabi PR², Miles EA³, Smith DE², Almehmadi A³, Alshathry A³, Childs CE³, Del Fabbro S³, Beavis J³, Moyses HE⁴, Clough GF³, Sethi JK⁵, Patel J⁶, Wright M⁶, Breen DJ⁷, Peebles C⁷, Darekar A⁸, Aspinall R⁹, Fowell AJ⁹, Dowman JK⁹, Nobili V¹⁰, Targher G¹¹, Delzenne NM¹², Bindels LB¹², Calder PC¹³, Byrne CD². Gastroenterology. 2020 Jan 24. pii: S0016-5085(20)30124-4. doi: 10.1053/j.gastro.2020.01.031. [Epub ahead of print]

193.	Work up of fatty liver by primary care physicians, review
	Rikhi R¹, Singh T², Modaresi Esfeh J². Ann Med Surg (Lond). 2020 Jan 11;50:41-48. doi: 10.1016/j.amsu.2020.01.001. eCollection 2020 Feb.

194.	NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
	Colca J^1,2. Expert Opin Investig Drugs. 2020 Jan 23:1-6. doi: 10.1080/13543784.2020.1715940. [Epub ahead of print]

195.	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
	Albhaisi S¹, Sanyal AJ². Pharmaceut Med. 2019 Dec;33(6):451-463. doi: 10.1007/s40290-019-00305-z.

196.	Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
	Oates JR^1,2,3, McKell MC^1,3,4, Moreno-Fernandez ME^1,2, Damen MSMA^1,2, Deepe GS Jr⁵, Qualls JE^1,3,4, Divanovic S^1,2,3,6. Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.

197.	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016
	Paik JM¹, Henry L², Golabi P¹, Alqahtani SA³, Trimble G⁴, Younossi ZM^1,4. Open Forum Infect Dis. 2020 Jan 7;7(1):ofz509. doi: 10.1093/ofid/ofz509. eCollection 2020 Jan.

198.	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
	Mantovani A¹, Byrne CD², Scorletti E³, Mantzoros CS⁴, Targher G⁵. Diabetes Metab. 2020 Jan 7. pii: S1262-3636(20)30002-1. doi: 10.1016/j.diabet.2019.12.007. [Epub ahead of print]

199.	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
	Romero FA, Jones C, Xu Y, Fenaux M, Halcomb RL. J Med Chem. 2020 Jan 13. doi: 10.1021/acs.jmedchem.9b01701. [Epub ahead of print]

200.	A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression
	Delacôte C¹, Bauvin P¹, Louvet A², Dautrecque F³, Ntandja Wandji LC³, Lassailly G², Voican C⁴, Perlemuter G⁴, Naveau S⁴, Mathurin P², Deuffic-Burban S⁵. Clin Gastroenterol Hepatol. 2020 Jan 10. pii: S1542-3565(20)30039-2. doi: 10.1016/j.cgh.2019.12.041. [Epub ahead of print]

201.	Small but mighty: Platelets in NASH and other chronic liver diseases
	Hilscher MB¹, Shah VH¹. Hepatology. 2020 Jan 5. doi: 10.1002/hep.31101. [Epub ahead of print]

202.	Continued muscle loss increases mortality in cirrhosis- impact of etiology of liver disease
	Welch N^1,2, Dasarathy J³, Runkana A⁴, Penumatsa R², Bellar A², Reen J², Rotroff D⁵, McCullough AJ¹, Dasarathy S^1,2. Liver Int. 2019 Dec 31. doi: 10.1111/liv.14358. [Epub ahead of print]

203.	Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?
	Fitzpatrick E¹, Dhawan A¹. J Clin Exp Hepatol. 2019 Nov-Dec;9(6):716-722. doi: 10.1016/j.jceh.2019.05.005. Epub 2019 May 31.

204.	Carotenoids and fatty liver disease: Current knowledge and research gaps
	Clugston RD¹. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Jan 2:158597. doi: 10.1016/j.bbalip.2019.158597. [Epub ahead of print]

205.	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression
	Du K¹, Chitneni SK², Suzuki A¹, Wang Y¹, Henao R³, Hyun J¹, Premont RT¹, Naggie S⁴, Moylan CA¹, Bashir MR⁵, Abdelmalek MF¹, Diehl AM⁶. Cell Mol Gastroenterol Hepatol. 2019 Dec 24. pii: S2352-345X(19)30182-1. doi: 10.1016/j.jcmgh.2019.12.006. [Epub ahead of print]

206.

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison SA¹, Goodman Z², Jabbar A³, Vemulapalli R⁴, Younes ZH⁵, Freilich B⁶, Sheikh MY⁷, Schattenberg JM⁸, Kayali Z⁹, Zivony A¹⁰, Sheikh A¹¹, Garcia-Samaniego J¹², Satapathy SK¹³, Therapondos G¹⁴, Mena E¹⁵, Schuppan D¹⁶, Robinson J¹⁷, Chan JL¹⁷, Hagerty DT¹⁸, Sanyal AJ¹⁹. J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]

207.	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH
	Gawrieh S¹, Guo X², Tan J², Lauzon M², Taylor KD², Loomba R³, Cummings OW⁴, Pillai S⁵, Bhatnagar P⁵, Kowdley KV⁶, Yates K⁷, Wilson LA⁷, Chen YI², Rotter JI², Chalasani N¹; NASH Clinical Research Network. Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.

208.	Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review
	Saeed N¹, Nadeau B¹, Shannon C², Tincopa M¹. Nutrients. 2019 Dec 16;11(12). pii: E3064. doi: 10.3390/nu11123064.

209.	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
	Baratta F¹, Pastori D², Angelico F³, Balla A⁴, Paganini AM⁴, Cocomello N¹, Ferro D¹, Violi F⁵, Sanyal AJ⁶, Del Ben M¹. Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31506-X. doi: 10.1016/j.cgh.2019.12.026. [Epub ahead of print]

210.	When the Liver Gets Stiff, the Tough Get Moving
	Nguyen TH¹, Wardell R¹, Chitturi S¹, Teoh N¹, Farrell G^1,2. J Gastroenterol Hepatol. 2019 Dec 22. doi: 10.1111/jgh.14963. [Epub ahead of print]

211.	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension
	Zhao YC^1,2, Zhao GJ^1,2, Chen Z^1,2, She ZG^1,2,3,4, Cai J^1,5,2, Li H^1,2,3. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419. Epub 2019 Dec 23.

212.	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic FattyLiver Disease in Patients With Crohn
	McHenry S¹, Tirath A², Tsai R³, Sharma Y⁴, Flores AG¹, Davidson NO¹, Fowler KJ^3,5, Ciorba MA^1,4, Deepak P^1,6. Inflamm Bowel Dis. 2020 Jan 7. pii: izz324. doi: 10.1093/ibd/izz324. [Epub ahead of print]

213.	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
	Coccia F¹, Testa M¹, Guarisco G¹, Bonci E², Di Cristofano C³, Silecchia G⁴, Leonetti F⁵, Gastaldelli A⁶, Capoccia D¹. Endocrine. 2019 Dec 19. doi: 10.1007/s12020-019-02155-w. [Epub ahead of print]

214.

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension

Garcia-Tsao G¹, Bosch J², Kayali Z³, Harrison SA⁴, Abdelmalek MF⁵, Lawitz E⁶, Satapathy SK⁷, Ghabril M⁸, Shiffman ML⁹, Younes ZH¹⁰, Thuluvath PJ¹¹, Berzigotti A¹², Albillos A¹³, Robinson JM¹⁴, Hagerty DT¹⁴, Chan JL¹⁴, Sanyal AJ¹⁵; IDN-6556-14 Investigators. J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]

215.	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?
	Petroni ML¹, Brodosi L¹, Marchignoli F¹, Musio A¹, Marchesini G¹. Nutrients. 2019 Dec 13;11(12). pii: E3048. doi: 10.3390/nu11123048.

216.	Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
	Cai H¹, Qin YL¹, Shi ZY¹, Chen JH¹, Zeng MJ¹, Zhou W¹, Chen RQ¹, Chen ZY². BMC Gastroenterol. 2019 Dec 18;19(1):219. doi: 10.1186/s12876-019-1132-8.

217.	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy
	Sattari M¹, Bril F², Egerman R^2,3, Kalavalapalli S⁴, Cusi K^4,5,6. J Investig Med. 2019 Dec 17. pii: jim-2019-001186. doi: 10.1136/jim-2019-001186. [Epub ahead of print]

218.	Bariatric Surgery in Cirrhotic Patients: Is It Safe?
	Younus H¹, Sharma A¹, Miquel R¹, Quaglia A¹, Kanchustambam SR¹, Carswell KA¹, Patel AG². Obes Surg. 2019 Dec 18. doi: 10.1007/s11695-019-04214-7. [Epub ahead of print]

219.	Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
	Tarantino G¹, Citro V², Capone D³. J Clin Med. 2019 Dec 19;9(1). pii: E15. doi: 10.3390/jcm9010015.

220.	Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients
	Gordon S¹, Fraysse J², Li S³, Ozbay AB², Wong RJ⁴. Am J Gastroenterol. 2019 Dec 12. doi: 10.14309/ajg.0000000000000484. [Epub ahead of print]

221.	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease
	Danford CJ¹, Jiang ZG¹, Salomaa V², Färkkilä M³, Jula A², Männistö S², Lundqvist A², Valsta L², Perola M², Åberg F^4,5. Hepatol Commun. 2019 Oct 10;3(12):1704-1705. doi: 10.1002/hep4.1437. eCollection 2019 Dec.

222.	Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features
	Bullón-Vela V¹, Abete I², Tur JA³, Pintó X⁴, Corbella E⁴, Martínez-González MA⁵, Toledo E⁵, Corella D⁶, Macías M⁷, Tinahones F⁷, Fitó M⁸, Estruch R⁹, Ros E¹⁰, Salas-Salvadó J¹¹, Daimiel L¹², Zulet MA¹³, Martínez JA²; PREDIMED Plus investigators. Nutrition. 2019 Oct 25;71:110620. doi: 10.1016/j.nut.2019.110620. [Epub ahead of print]

223.	Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity
	Peña-Vélez R^1,2, Garibay-Nieto N^1,2,3, Cal-Y-Mayor-Villalobos M⁴, Laresgoiti-Servitje E⁵, Pedraza-Escudero K^1,2, García-Blanco MDC⁴, Heredia-Nieto OA⁶, Villanueva-Ortega E^1,2. J Pediatr Endocrinol Metab. 2019 Dec 16. pii: /j/jpem.ahead-of-print/jpem-2019-0204/jpem-2019-0204.xml. doi: 10.1515/jpem-2019-0204. [Epub ahead of print]

224.	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver DiseaseAnd Non-Alcoholic Steatohepatitis
	Ganguli S¹, DeLeeuw P², Satapathy SK³. Hepat Med. 2019 Nov 15;11:159-178. doi: 10.2147/HMER.S188991. eCollection 2019.

225.	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
	Plaz Torres MC^1,2,3, Aghemo A^3,4, Lleo A^3,4, Bodini G^1,2,3, Furnari M¹, Marabotto E¹, Miele L⁵, Giannini EG^1,2,6. Nutrients. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971.

226.	Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study
	van den Berg EH^1,2, Gruppen EG^1,3, Blokzijl H², Bakker SJL³, Dullaart RPF¹. J Clin Med. 2019 Dec 6;8(12). pii: E2157. doi: 10.3390/jcm8122157.

227.	High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths
	De Chiara F¹, Ureta Checcllo C², Ramón Azcón J¹. Nutrients. 2019 Dec 6;11(12). pii: E2985. doi: 10.3390/nu11122985.

228.	A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease
	Chu X¹, Karasinski K², Donellan S², Kaniper S², Wood GC¹, Shi W¹, Edwards MA³, Soans R³, Still CD¹, Gerhard GS⁴. Langenbecks Arch Surg. 2019 Dec 11. doi: 10.1007/s00423-019-01848-0. [Epub ahead of print]

229.	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
	Siddiqui MS1, Van Natta ML2, Connelly MA3, Vuppalanchi R4, Neuschwander-Tetri BA5, Tonascia J2, Guy C6, Loomba R7, Dasarathy S8, Wattacheril J9, Chalasani N4, Sanyal AJ10; NASH CRN. J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]

230.	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
	Mouries J¹, Brescia P¹, Silvestri A¹, Spadoni I², Sorribas M³, Wiest R⁴, Mileti E⁵, Galbiati M⁶, Invernizzi P⁶, Adorini L⁷, Penna G⁸, Rescigno M⁹. J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.

231.	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
	Ratziu V¹, Sanyal AJ², Loomba R³, Rinella M⁴, Harrison S⁵, Anstee QM⁶, Goodman Z⁷, Bedossa P⁸, MacConell L⁹, Shringarpure R⁹, Shah A⁹, Younossi Z⁷. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

232.	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
	Loomba R¹, Sanyal AJ², Kowdley KV³, Terrault N⁴, Chalasani NP⁵, Abdelmalek MF⁶, McCullough AJ⁷, Shringarpure R⁸, Ferguson B⁸, Lee L⁸, Chen J⁸, Liberman A⁸, Shapiro D⁸, Neuschwander-Tetri BA⁹. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.

233.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi ZM¹, Ratziu V², Loomba R³, Rinella M⁴, Anstee QM⁵, Goodman Z¹, Bedossa P⁶, Geier A⁷, Beckebaum S⁸, Newsome PN⁹, Sheridan D¹⁰, Sheikh MY¹¹, Trotter J¹², Knapple W¹³, Lawitz E¹⁴, Abdelmalek MF¹⁵, Kowdley KV¹⁶, Montano-Loza AJ¹⁷, Boursier J¹⁸, Mathurin P¹⁹, Bugianesi E²⁰, Mazzella G²¹, Olveira A²², Cortez-Pinto H²³, Graupera I²⁴, Orr D²⁵, Gluud LL²⁶, Dufour JF²⁷, Shapiro D²⁸, Campagna J²⁸, Zaru L²⁸, MacConell L²⁸, Shringarpure R²⁸, Harrison S²⁹, Sanyal AJ³⁰; REGENERATE Study Investigators.

Collaborators (336) Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]

234.	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
	Poynard T^1,2, Peta V^2,3, Deckmyn O³, Pais R^1,2, Ngo Y^2,3, Charlotte F⁴, Ngo A³, Munteanu M^2,3, Imbert-Bismut F⁵, Monneret D⁵, Housset C², Thabut D^1,2, Valla D⁶, Boitard C⁷, Castera L⁶, Ratziu V¹; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.

235.	The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD
	Balakrishnan M¹, Loomba R^2,3. J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284. [Epub ahead of print]

236.	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany
	Labenz C^1,2, Huber Y^1,2, Michel M^1,2, Nagel M^1,2, Galle PR^1,2, Kostev K³, Schattenberg JM^4,5. Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]

237.	New drugs for NAFLD: lessons from basic models to the clinic
	Reimer KC¹, Wree A², Roderburg C², Tacke F³. Hepatol Int. 2019 Dec 4. doi: 10.1007/s12072-019-10001-4. [Epub ahead of print]

238.	Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
	Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. J Clin Invest. 2019 Dec 5. pii: 134165. doi: 10.1172/JCI134165. [Epub ahead of print]

239.	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
	Pedrosa M¹, Seyedkazemi S², Francque S³, Sanyal A⁴, Rinella M⁵, Charlton M⁶, Loomba R⁷, Ratziu V⁸, Kochuparampil J¹, Fischer L², Vaidyanathan S⁹, Anstee QM¹⁰. Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]

240.	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
	Shili-Masmoudi S¹, Wong GL^2,3, Hiriart JB¹, Liu K^4,5, Chermak F¹, Shu SS^2,3, Foucher J¹, Tse YK^2,3, Bernard PH¹, Yip TC^2,3, Merrouche W¹, Chan HL^2,3, Wong VW^2,3, de Lédinghen V^1,6. Liver Int. 2019 Nov 20. doi: 10.1111/liv.14301. [Epub ahead of print]

241.	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
	Thondam SK¹, Cuthbertson DJ², Wilding JPH³. Peptides. 2019 Nov 20:170208. doi: 10.1016/j.peptides.2019.170208. [Epub ahead of print]

242.	Moderate alcohol use in fatty liver disease; don
	Gow P^1,2, Testro AG^1,2, Hey P^1,2, Sinclair M^1,2. Hepatology. 2019 Nov 29. doi: 10.1002/hep.31049. [Epub ahead of print]

243.	Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
	Blazina I¹, Selph S². Syst Rev. 2019 Nov 29;8(1):295. doi: 10.1186/s13643-019-1200-8.

244.	Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria
	Baldwin D¹, Chennakesavalu M¹, Gangemi A². Surg Obes Relat Dis. 2019 Sep 18. pii: S1550-7289(19)30997-9. doi: 10.1016/j.soard.2019.09.060. [Epub ahead of print]

245.	Attributable Fractions of NAFLD for Mortality in the United States: Results From NHANES III With 27 Years of Follow-up
	Alvarez CS¹, Graubard BI¹, Thistle JE¹, Petrick JL^1,2, McGlynn KA¹. Hepatology. 2019 Nov 16. doi: 10.1002/hep.31040. [Epub ahead of print]

246.	Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease
	Long MT¹, Massaro JM², Hoffmann U³, Benjamin EJ⁴, Naimi TS⁵. Clin Gastroenterol Hepatol. 2019 Nov 14. pii: S1542-3565(19)31309-6. doi: 10.1016/j.cgh.2019.11.022. [Epub ahead of print]

247.	Hypothetical Treatment of Patients with Nonalcoholic Steatohepatitis: Potential Impact on Important Clinical Outcomes
	Younossi ZM^1,2, Tampi RP¹, Nader F³, Younossi IM³, Cable R², Srishord M², Racila A^1,3. Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292. [Epub ahead of print]

248.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

Best J¹, Bechmann LP¹, Sowa JP¹, Sydor S¹, Dechêne A², Pflanz K³, Bedreli S³, Schotten C³, Geier A⁴, Berg T⁵, Fischer J⁵, Vogel A⁶, Bantel H⁶, Weinmann A⁷, Schattenberg JM⁷, Huber Y⁷, Wege H⁸, von Felden J⁸, Schulze K⁸, Bettinger D⁹, Thimme R¹⁰, Sinner F¹, Schütte K¹, Weiss KH¹¹, Toyoda H¹², Yasuda S¹², Kumada T¹³, Berhane S¹⁴, Wichert M¹⁵, Heider D¹⁶, Gerken G³, Johnson P¹⁴, Canbay A¹⁷. Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]

249.	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
	Harrison SA¹, Bashir MR², Guy CD², Zhou R³, Moylan CA², Frias JP⁴, Alkhouri N⁵, Bansal MB⁶, Baum S⁷, Neuschwander-Tetri BA⁸, Taub R⁹, Moussa SE¹⁰. Lancet. 2019 Nov 11. pii: S0140-6736(19)32517-6. doi: 10.1016/S0140-6736(19)32517-6. [Epub ahead of print]

250.	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
	Pennisi G¹, Celsa C¹, Spatola F¹, Dallio M², Federico A², Petta S¹. Int J Environ Res Public Health. 2019 Nov 7;16(22). pii: E4334. doi: 10.3390/ijerph16224334.

251.	Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
	Kashyap ML¹, Ganji S², Nakra NK², Kamanna VS³. J Clin Lipidol. 2019 Oct 14. pii: S1933-2874(19)30290-9. doi: 10.1016/j.jacl.2019.10.006. [Epub ahead of print]

252.	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
	Pennisi G¹, Celsa C¹, Giammanco A², Spatola F¹, Petta S¹. Int J Mol Sci. 2019 Nov 9;20(22). pii: E5613. doi: 10.3390/ijms20225613.

253.	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
	Harrison SA¹, Alkhouri N², Davison BA³, Sanyal A⁴, Edwards C³, Colca JR⁵, Lee BH⁵, Loomba R⁶, Cusi K⁷, Kolterman O⁸, Cotter G³, Dittrich HC⁵. J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

254.	Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis
	Young S¹, Sanghvi T², Rubin N³, Hall D³, Roller L³, Charaf Y³, Golzarian J³. Cardiovasc Intervent Radiol. 2019 Nov 4. doi: 10.1007/s00270-019-02363-x. [Epub ahead of print]

255.	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease
	Kanwal F^1,2,3, Kramer J^2,3, Li L⁴, Dai J⁴, Natarajan Y¹, Yu X^2,3, Asch SM^5,6, El-Serag HB^1,2,3. Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014. [Epub ahead of print]

256.	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
	Moolla A^1,2, Motohashi K¹, Marjot T^1,3, Shard A³, Ainsworth M³, Gray A⁴, Holman R^2,5, Pavlides M^2,3, Ryan JD^2,3, Tomlinson JW^1,2, Cobbold JF^2,3. Frontline Gastroenterol. 2019 Oct;10(4):337-346. doi: 10.1136/flgastro-2018-101155. Epub 2019 Apr 30.

257.	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
	Paik JM¹, Henry L², De Avila L¹, Younossi E¹, Racila A¹, Younossi ZM^1,3. Hepatol Commun. 2019 Aug 14;3(11):1459-1471. doi: 10.1002/hep4.1419. eCollection 2019 Nov.

258.	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol
	Labenz C¹, Prochaska JH^2,3,4, Huber Y¹, Nagel M¹, Straub BK⁵, Wild P^2,3,4, Galle PR¹, Schattenberg JM^1,6. Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.

259.	Hepatocellular carcinoma and non-alcoholic fatty liver disease
	Golabi P^1,2, Rhea L¹, Henry L², Younossi ZM^3,4. Hepatol Int. 2019 Nov 7. doi: 10.1007/s12072-019-09995-8. [Epub ahead of print]

260.	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
	Navarro VJ¹, Belle SH², D'Amato M³, Adfhal N⁴, Brunt EM⁵, Fried MW⁶, Reddy KR⁷, Wahed AS², Harrison S⁸; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019.

261.	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
	Sebastiani G^1,2, Saeed S³, Lebouche B¹, de Pokomandy A¹, Szabo J¹, Haraoui LP¹, Routy JP^1,4, Wong P², Deschenes M², Ghali P², Klein M¹; LIVEHIV Study Group. AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002412. [Epub ahead of print]

262.	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
	Morrison M¹, Hughes HY^2,3, Naggie S^4,5, Syn WK^6,7,8. Dig Dis Sci. 2019 Oct 23. doi: 10.1007/s10620-019-05861-7. [Epub ahead of print]

263.	Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease
	Seth A¹, Orkin S², Yodoshi T², Liu C³, Fei L³, Hardy J², Trout AT⁴, Arce Clachar AC², Bramlage K², Xanthakos S², Mouzaki M². Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]

264.	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
	Younossi ZM^1,2, Tampi RP³, Racila A^3,2, Qiu Y⁴, Burns L⁴, Younossi I⁵, Nader F⁵. Diabetes Care. 2019 Oct 28. pii: dc191113. doi: 10.2337/dc19-1113. [Epub ahead of print]

265.	Polycystic Ovary Syndrome (PCOS) Is Associated With NASH Severity and Advanced Fibrosis
	Sarkar M¹, Terrault N², Chan W¹, Cedars M³, Huddleston H³, Duwaerts CC¹, Balitzer D⁴, Gill RM⁴. Liver Int. 2019 Oct 18. doi: 10.1111/liv.14279. [Epub ahead of print]

266.	Decreased Physical Working Capacity in Adolescents With Non-Alcoholic Fatty Liver DiseaseAssociates With Reduced Iron Availability: PWC in NAFLD Relates to Iron Bioavailability
	Mitchell T¹, McKinnon E², Ayonrinde O³, Adams LA⁴, Trinder D⁵, Chua ACG⁵, Newton RU⁶, Straker L⁷, Olynyk JK⁸. Clin Gastroenterol Hepatol. 2019 Oct 16. pii: S1542-3565(19)31116-4. doi: 10.1016/j.cgh.2019.10.017. [Epub ahead of print]

267.	Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease
	Packer M¹. Am J Med. 2019 Oct 14. pii: S0002-9343(19)30843-5. doi: 10.1016/j.amjmed.2019.09.002. [Epub ahead of print]

268.	Effect of alcohol consumption on nonalcoholic fatty liver disease
	Weng G¹, Dunn W¹. Transl Gastroenterol Hepatol. 2019 Sep 17;4:70. doi: 10.21037/tgh.2019.09.02. eCollection 2019.

269.	Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management
	Marjot T^1,2, Moolla A², Cobbold JF¹, Hodson L², Tomlinson JW². Endocr Rev. 2019 Oct 20. pii: bnz009. doi: 10.1210/endrev/bnz009. [Epub ahead of print]

270.	Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
	Loomba R^1,2, Adams LA^3,4. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]

271.	MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH)
	Al-Sharhan F¹, Dohan A², Barat M³, Feddal A⁴, Terris B⁵, Pol S⁶, Mallet V⁷, Soyer P⁸. Eur J Radiol. 2019 Oct;119:108648. doi: 10.1016/j.ejrad.2019.108648. Epub 2019 Sep 7.

272.	Dietary cholesterol does not break your heart but kills your liver
	Püschel GP¹, Henkel J¹. Porto Biomed J. 2019 Jun 29;3(1):e12. doi: 10.1016/j.pbj.0000000000000012. eCollection 2018 Aug.

273.	Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease
	Cimini FA¹, Barchetta I¹, Carotti S², Morini S³, Cavallo MG¹. World J Gastrointest Pathophysiol. 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.

274.	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
	Stanley TL¹, Fourman LT¹, Feldpausch MN¹, Purdy J², Zheng I¹, Pan CS¹, Aepfelbacher J², Buckless C³, Tsao A³, Kellogg A⁴, Branch K⁵, Lee H⁶, Liu CY⁷, Corey KE⁸, Chung RT⁸, Torriani M³, Kleiner DE⁹, Hadigan CM², Grinspoon SK¹⁰. Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]

275.	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study
	Cleveland ER¹, Ning H², Vos MB³, Lewis CE⁴, Rinella ME¹, Carr JJ⁵, Lloyd-Jones DM^2,6, VanWagner LB^7,8. J Gen Intern Med. 2019 Oct 8. doi: 10.1007/s11606-019-05340-9. [Epub ahead of print]

276.	Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?
	Tarantino G¹, Citro V², Conforti P³, Balsano C⁴, Capone D⁵. J Clin Med. 2019 Sep 20;8(10). pii: E1510. doi: 10.3390/jcm8101510.

277.	Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
	Alexander M¹, Loomis AK², van der Lei J³, Duarte-Salles T⁴, Prieto-Alhambra D⁵, Ansell D^6,7, Pasqua A⁸, Lapi F⁸, Rijnbeek P³, Mosseveld M³, Avillach P^3,9, Egger P¹, Dhalwani NN¹⁰, Kendrick S¹¹, Celis-Morales C¹², Waterworth DM¹³, Alazawi W¹⁴, Sattar N¹². BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.

278.	Chronic hepatitis B and NASH: Is "fat" all bad?
	Li J¹, Cheung RC^2,3, Nguyen MH³. Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983. [Epub ahead of print]

279.	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
	Lazarus JV¹, Ekstedt M², Marchesini G³, Mullen J⁴, Novak K⁵, Pericàs JM⁶, Roel E⁷, Romero-Gómez M⁸, Ratziu V⁹, Tacke F¹⁰, Cortez-Pinto H¹¹, Anstee QM¹²; EASL International Liver Foundation NAFLD Policy Review Collaborators. J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]

280.	Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults
	Shin A¹, Xu H², Imperiale TF^1,3. BMJ Open Gastroenterol. 2019 Aug 12;6(1):e000322. doi: 10.1136/bmjgast-2019-000322. eCollection 2019.

281.	Genetic Causes of Liver Disease: When to Suspect a Genetic Etiology, Initial Lab Testing, and the Basics of Management
	Schonfeld EA¹, Brown RS Jr². Med Clin North Am. 2019 Nov;103(6):991-1003. doi: 10.1016/j.mcna.2019.07.003.

282.	Impact of a preoperative low-calorie diet on liver histology in patients with fatty liver diseaseundergoing bariatric surgery
	Wolf RM¹, Oshima K², Canner JK³, Steele KE⁴. Surg Obes Relat Dis. 2019 Aug 22. pii: S1550-7289(19)30380-6. doi: 10.1016/j.soard.2019.08.013. [Epub ahead of print]

283.	Metabolic profiling of adolescent non-alcoholic fatty liver disease
	Hartley A^1,2,3, Santos Ferreira DL^2,3, Anderson EL^2,3, Lawlor DA^2,3. Version 2. Wellcome Open Res. 2019 Sep 19 [revised 2019 Sep 19];3:166. doi: 10.12688/wellcomeopenres.14974.2. eCollection 2018.

284.	Reversal of NASH fibrosis with pharmacotherapy
	Alukal JJ¹, Thuluvath PJ^2,3. Hepatol Int. 2019 Sep;13(5):534-545. doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30.

285.	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
	Younossi ZM^1,2, Stepanova M³, Lawitz EJ⁴, Reddy KR⁵, Wai-Sun Wong V⁶, Mangia A⁷, Muir AJ⁸, Jacobson I⁹, Djedjos CS¹⁰, Gaggar A¹⁰, Myers RP¹⁰, Younossi I³, Nader F³, Racila A³. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375.

286.	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
	Doumas M¹, Imprialos K^1,2, Stavropoulos K^1,2, Athyros VG^1,2. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.

287.	Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic FattyLiver Disease: A Case-control Study
	German MN^1,2, Lutz MK^1,2, Pickhardt PJ^2,3, Bruce RJ^2,3, Said A^1,2. J Clin Gastroenterol. 2019 Sep 17. doi: 10.1097/MCG.0000000000001260. [Epub ahead of print]

288.	Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liverdisease in the United States
	Adejumo AC^1,2,3,4, Samuel GO⁵, Adegbala OM⁶, Adejumo KL⁴, Ojelabi O³, Akanbi O⁷, Ogundipe OA⁸, Pani L^1,2. Ann Gastroenterol. 2019 Sep-Oct;32(5):504-513. doi: 10.20524/aog.2019.0402. Epub 2019 Jul 17.

289.	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic FattyLiver Disease Who Have Normal Aminotransferase Levels
	Gawrieh S¹, Wilson LA², Cummings OW³, Clark JM², Loomba R⁴, Hameed B⁵, Abdelmalek MF⁶, Dasarathy S⁷, Neuschwander-Tetri BA⁸, Kowdley K⁹, Kleiner D¹⁰, Doo E¹¹, Tonascia J², Sanyal A¹², Chalasani N¹; and the NASH Clinical Research Network. Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.

290.	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
	Gawrieh S¹, Dakhoul L¹, Miller E², Scanga A³, deLemos A⁴, Kettler C¹, Burney H¹, Liu H¹, Abu-Sbeih H², Chalasani N¹, Wattacheril J⁵. Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.

291.	Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty LiverDisease: A Cross-Sectional Study
	Blackett JW¹, Verna EC², Lebwohl B^2,3. Dig Dis. 2019 Aug 30:1-9. doi: 10.1159/000502684. [Epub ahead of print]

292.	Multi-drug approaches to NASH: what's in the development pipeline?
	Johnston MP¹, Patel J¹, Byrne CD^2,3. Expert Opin Investig Drugs. 2019 Sep 23:1-8. doi: 10.1080/13543784.2020.1668926. [Epub ahead of print]

293.	ANNALS EXPRESS: A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of Chronic Liver Disease
	Patel P¹, Connoley D¹, Jones F¹, Srivastava A¹, Rosenberg W¹. Ann Clin Biochem. 2019 Sep 17:4563219879962. doi: 10.1177/0004563219879962. [Epub ahead of print]

294.	Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
	Thiagarajan P¹, Aithal GP¹. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):515-521. doi: 10.1016/j.jceh.2019.03.002. Epub 2019 Mar 13.

295.	Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
	Choudhary NS¹, Duseja A². J Clin Exp Hepatol. 2019 Jul-Aug;9(4):506-514. doi: 10.1016/j.jceh.2019.02.005. Epub 2019 Feb 15.

296.	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective
	Samji NS¹, Verma R^1,2, Satapathy SK³. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):497-505. doi: 10.1016/j.jceh.2019.05.001. Epub 2019 May 16.

297.	HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease
	McCullough A¹, Previs SF², Dasarathy J³, Lee K⁴, Osme A⁴, Kim C⁴, Ilchenko S⁴, Lorkowski SW⁵, Smith JD⁵, Dasarathy S¹, Kasumov T⁶. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]

298.	Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective
	Ching-Yeung Yu B¹, Kwok D¹, Wong VW¹. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):491-496. doi: 10.1016/j.jceh.2019.01.007. Epub 2019 Feb 7.

299.	Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
	Loomba R^1,2, Adams LA^3,4. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]

300.	Nicotinamide and NAFLD: Is There Nothing New Under the Sun?
	Guarino M^1,2, Dufour JF^3,4. Metabolites. 2019 Sep 10;9(9). pii: E180. doi: 10.3390/metabo9090180.

301.	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
	Liebig S¹, Stoeckmann N¹, Geier A², Rau M², Schattenberg JM³, Bahr MJ⁴, Manns MP¹, Jaeckel E¹, Schulze-Osthoff K⁵, Bantel H¹. Clin Transl Gastroenterol. 2019 Aug;10(8):e00066. doi: 10.14309/ctg.0000000000000066.

302.	HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease
	McCullough A¹, Previs SF², Dasarathy J³, Lee K⁴, Osme A⁴, Kim C⁴, Ilchenko S⁴, Lorkowski SW⁵, Smith JD⁵, Dasarathy S¹, Kasumov T⁶. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]

303.	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
	Drescher HK¹, Weiskirchen S², Weiskirchen R³. Cells. 2019 Aug 7;8(8). pii: E845. doi: 10.3390/cells8080845.

304.	Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study
	Reddavide R¹, Cisternino AM¹, Inguaggiato R¹, Rotolo O¹, Zinzi I¹, Veronese N¹, Guerra V², Fucilli F³, Di Giovanni G³, Leandro G⁴, Giannico S¹, Caruso MG⁵. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.

305.	The decreasing predictive power of MELD in an era of changing etiology of liverdisease
	Godfrey EL¹, Malik TH¹, Lai JC², Mindikoglu AL^1,3, Galván NTN¹, Cotton RT¹, O'Mahony CA¹, Goss JA¹, Rana A¹. Am J Transplant. 2019 Aug 8. doi: 10.1111/ajt.15559. [Epub ahead of print]

306.	Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis
	Chen VL^1,2, Wright AP^1,3, Halligan B¹, Chen Y¹, Du X¹, Handelman SK^1,2, Long MT⁴, Kiel DP^5,6, Speliotes EK^1,2. Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug.

307.	Nonalcoholic Fatty Liver Identification and Characterization Using Big Data
	Goldshtein I¹, Chodick G², Kochba I³, Gal N³, Webb M⁴, Shibolet O⁵. Clin Gastroenterol Hepatol. 2019 Aug 9. pii: S1542-3565(19)30863-8. doi: 10.1016/j.cgh.2019.08.007. [Epub ahead of print]

308.	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
	Younossi ZM^1,2, Stepanova M³, Lawitz EJ⁴, Reddy KR⁵, Wai-Sun Wong V⁶, Mangia A⁷, Muir AJ⁸, Jacobson I⁹, Djedjos CS¹⁰, Gaggar A¹⁰, Myers RP¹⁰, Younossi I³, Nader F³, Racila A³. Am J Gastroenterol. 2019 Aug 20. doi: 10.14309/ajg.0000000000000375. [Epub ahead of print]

309.	Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study
	Reddavide R¹, Cisternino AM¹, Inguaggiato R¹, Rotolo O¹, Zinzi I¹, Veronese N¹, Guerra V², Fucilli F³, Di Giovanni G³, Leandro G⁴, Giannico S¹, Caruso MG⁵. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.

310.	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
	Chen F¹, Esmaili S^1,2, Rogers G³, Bugianesi E⁴, Petta S⁵, Marchesini G⁶, Bayoumi A¹, Metwally M¹, Azardaryany MK¹, Coulter S¹, Choo JM³, Younes R⁴, Rosso C⁴, Liddle C¹, Adams LA⁷, Craxì A⁵, George J¹, Eslam M¹. Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

311.	The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study
	Allen AM¹, Hicks SB², Mara KC³, Larson JJ³, Therneau TM³. J Hepatol. 2019 Aug 27. pii: S0168-8278(19)30485-4. doi: 10.1016/j.jhep.2019.08.018. [Epub ahead of print]

312.	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
	Drescher HK¹, Weiskirchen S², Weiskirchen R³. Cells. 2019 Aug 7;8(8). pii: E845. doi: 10.3390/cells8080845.

313.	Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes
	Hershman M¹, Mei R¹, Kushner T¹. Gastroenterol Hepatol (N Y). 2019 Apr;15(4):221-228.

314.	Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post LiverTransplant: Systematic Review and Meta-analysis
	Saeed N¹, Glass L¹, Sharma P¹, Shannon C², Sonnenday CJ³, Tincopa MA¹. Transplantation. 2019 Aug 12. doi: 10.1097/TP.0000000000002916. [Epub ahead of print]

315.	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-AlcoholicSteatohepatitis?
	Doumas M¹, Imprialos K^1,2, Stavropoulos K^1,2, Athyros VG^1,2. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.

316.	Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
	Abenavoli L¹, Boccuto L², Federico A³, Dallio M³, Loguercio C³, Di Renzo L⁴, De Lorenzo A⁴. Int J Environ Res Public Health. 2019 Aug 21;16(17). pii: E3011. doi: 10.3390/ijerph16173011.

317.	CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
	Pockros PJ¹, Fuchs M², Freilich B³, Schiff E⁴, Kohli A⁵, Lawitz EJ⁶, Hellstern PA⁷, Owens-Grillo J⁸, Van Biene C⁸, Shringarpure R⁸, MacConell L⁸, Shapiro D⁸, Cohen DE⁹. Liver Int. 2019 Aug 11. doi: 10.1111/liv.14209. [Epub ahead of print]

318.	Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
	Pandyarajan V¹, Gish RG¹, Alkhouri N¹, Noureddin M¹. Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365.

319.	Noninvasive Tests of Liver Fibrosis and Their Combination in NAFLD: From Selected Patients to Real-Life Populations
	Boursier J^1,2, Francque S^3,4. Hepatology. 2019 Aug 5. doi: 10.1002/hep.30886. [Epub ahead of print]

320.	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
	Golabi P¹, Fukui N², Paik J¹, Sayiner M², Mishra A², Younossi ZM^1,2. Hepatol Commun. 2019 Jun 6;3(8):1050-1060. doi: 10.1002/hep4.1387. eCollection 2019 Aug.

321.	Importance of fatigue and its measurement in chronic liver disease
	Gerber LH¹, Weinstein AA², Mehta R³, Younossi ZM⁴. World J Gastroenterol. 2019 Jul 28;25(28):3669-3683. doi: 10.3748/wjg.v25.i28.3669.

322.	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program
	Huber Y¹, Pfirrmann D², Gebhardt I¹, Labenz C¹, Gehrke N¹, Straub BK³, Ruckes C⁴, Bantel H⁵, Belda E⁶, Clément K⁷, Leeming DJ⁸, Karsdal MA⁸, Galle PR¹, Simon P², Schattenberg JM¹. Aliment Pharmacol Ther. 2019 Jul 25. doi: 10.1111/apt.15427. [Epub ahead of print]

323.	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
	Bril F¹, Biernacki DM¹, Kalavalapalli S¹, Lomonaco R¹, Subbarayan SK¹, Lai J², Tio F³, Suman A⁴, Orsak BK⁵, Hecht J⁶, Cusi K^7,8. Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167. Epub 2019 May 21.

324.	eNOS Deletion Impairs Mitochondrial Quality Control and Exacerbates Western Diet Induced NASH
	Sheldon RD¹, Meers GM¹, Morris EM², Linden MA¹, Cunningham RP¹, Ibdah JA³, Thyfault JP⁴, Laughlin MH⁵, Rector RS⁶. Am J Physiol Endocrinol Metab. 2019 Jul 30. doi: 10.1152/ajpendo.00096.2019. [Epub ahead of print]

325.	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
	Liebig S¹, Stoeckmann N¹, Geier A², Rau M², Schattenberg JM³, Bahr MJ⁴, Manns MP¹, Jaeckel E¹, Schulze-Osthoff K⁵, Bantel H¹. Clin Transl Gastroenterol. 2019 Aug 8. doi: 10.14309/ctg.0000000000000066. [Epub ahead of print]

326.	Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects
	Tsou P¹, Wu CJ². J Clin Med. 2019 Jul 19;8(7). pii: E1057. doi: 10.3390/jcm8071057.

327.	Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis
	Perry RJ¹. Obesity (Silver Spring). 2019 Jul 25. doi: 10.1002/oby.22559. [Epub ahead of print]

328.	Pocket-Sized Versus Conventional Ultrasound for Detecting Fatty Infiltration of the Liver
	Miles DA¹, Levi CS², Uhanova J¹, Cuvelier S¹, Hawkins K¹, Minuk GY^3,4. Dig Dis Sci. 2019 Aug 2. doi: 10.1007/s10620-019-05752-x. [Epub ahead of print]

329.	Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?
	Moris W^1,2,3, Verhaegh P^#2,3, Jonkers D^2,3, Deursen CV^1,2, Koek G^2,3,4. Semin Liver Dis. 2019 Jul 22. doi: 10.1055/s-0039-1693114. [Epub ahead of print]

330.	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis
	Crossan C¹, Majumdar A², Srivastava A², Thorburn D², Rosenberg W², Pinzani M², Longworth L^1,3, Tsochatzis EA². Liver Int. 2019 Jul 22. doi: 10.1111/liv.14198. [Epub ahead of print]

331.	Pathogenesis of NASH: The Impact of Multiple Pathways
	Noureddin M¹, Sanyal AJ². Curr Hepatol Rep. 2018 Dec;17(4):350-360. doi: 10.1007/s11901-018-0425-7. Epub 2018 Oct 31.

332.	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center
	Libman H¹, Jiang ZG¹, Tapper EB², Reynolds EE¹. Ann Intern Med. 2019 Aug 6;171(3):199-207. doi: 10.7326/M19-1125.

333.

Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes

Barata L¹, Feitosa MF¹, Bielak LF², Halligan B³, Baldridge AS⁴, Guo X⁵, Yerges-Armstrong LM⁶, Smith AV⁷, Yao J⁵, Palmer ND⁸, VanWagner LB^4,9, Carr JJ¹⁰, Chen YI⁵, Allison M¹¹, Budoff MJ¹², Handelman SK³, Kardia SLR², Mosley TH Jr¹³, Ryan K⁶, Harris TB¹⁴, Launer LJ¹⁴, Gudnason V^15,16, Rotter JI⁵, Fornage M¹⁷, Rasmussen-Torvik LJ⁴, Borecki IB¹, O'Connell JR⁶, Peyser PA², Speliotes EK³, Province MA¹. Hepatol Commun. 2019 Apr 18;3(7):894-907. doi: 10.1002/hep4.1353. eCollection 2019 Jul.

334.	Metabolic control of gene transcription in non-alcoholic fatty liver disease: the role of the epigenome
	Sinton MC¹, Hay DC², Drake AJ³. Clin Epigenetics. 2019 Jul 18;11(1):104. doi: 10.1186/s13148-019-0702-5.

335.	Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease
	Trout AT^1,2,3, Hunte DE⁴, Mouzaki M^5,6, Xanthakos SA^5,6, Su W⁷, Zhang B^5,8, Dillman JR^4,9. Abdom Radiol (NY). 2019 Jul 16. doi: 10.1007/s00261-019-02123-y. [Epub ahead of print]

336.	Clinically Significant Fibrosis is Associated With Longitudinal Increases in Fibrosis-4 and NAFLD Fibrosis Scores
	Patel PJ¹, Cheng JC², Banh X², Gracen L², Radford-Smith D³, Hossain F⁴, Horsfall LU¹, Lee Hayward K², Williams S⁴, Johnson T⁴, Brown NN⁵, Saad N⁶, Stuart KA⁷, Russell AW⁸, Valery PC⁹, Clouston AD², Irvine KM¹⁰, Bernard A¹¹, Powell EE¹². Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]

337.	Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
	Koopman N¹, Molinaro A², Nieuwdorp M³, Holleboom AG³. Aliment Pharmacol Ther. 2019 Aug 2. doi: 10.1111/apt.15416. [Epub ahead of print]

338.	Reversal of NASH fibrosis with pharmacotherapy
	Alukal JJ¹, Thuluvath PJ^2,3. Hepatol Int. 2019 Jul 30. doi: 10.1007/s12072-019-09970-3. [Epub ahead of print]

339.	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis
	Wong RJ¹, Tran T², Kaufman H³, Niles J³, Gish R⁴. PLoS One. 2019 Aug 1;14(8):e0220612. doi: 10.1371/journal.pone.0220612. eCollection 2019.

340.	Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
	Yang JD^1,2,3,4, Ahmed F¹, Mara KC⁵, Addissie BD⁶, Allen AM¹, Gores GJ¹, Roberts LR¹. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858. [Epub ahead of print]

341.	Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults
	Lee SB^#1,2, Kim MK^#3, Kang S^1,2, Park K^1,2, Kim JH^1,2, Baik SJ⁴, Nam JS^1,2, Ahn CW^1,2, Park JS^1,5. Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186. doi: 10.3803/EnM.2019.34.2.179.

342.	Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States
	Weintraub JA¹, Lopez Mitnik G², Dye BA². J Dent Res. 2019 Aug 1:22034519866442. doi: 10.1177/0022034519866442. [Epub ahead of print]

343.	Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype
	Erickson ML¹, Haus JM², Malin SK³, Flask CA⁴, McCullough AJ⁵, Kirwan JP⁶. Nutr Metab Cardiovasc Dis. 2019 Jun 21. pii: S0939-4753(19)30240-6. doi: 10.1016/j.numecd.2019.06.012. [Epub ahead of print]

344.	Epidemiology of chronic liver diseases in the USA in the past three decades
	Younossi ZM^1,2, Stepanova M³, Younossi Y³, Golabi P^4,2, Mishra A^4,2, Rafiq N^4,2, Henry L³. Gut. 2019 Jul 31. pii: gutjnl-2019-318813. doi: 10.1136/gutjnl-2019-318813. [Epub ahead of print]

345.	Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review
	Reddy AJ¹, George ES^1,2,3, Roberts SK⁴, Tierney AC^1,3,5. Nutr Rev. 2019 Jul 30. pii: nuz029. doi: 10.1093/nutrit/nuz029. [Epub ahead of print]

346.	Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B
	Choi HSJ^1,2, Brouwer WP³, Zanjir WMR¹, de Man RA³, Feld JJ¹, Hansen BE^1,3,4, Janssen HLA¹, Patel K¹. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857. [Epub ahead of print]

347.	ASKing no more: the emerging role of DUSP12 in the regulation of hepatic lipid metabolism
	Bubici C¹, Lepore A², Papa S². Hepatology. 2019 Jul 12. doi: 10.1002/hep.30851. [Epub ahead of print]

348.	Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners
	Shakir AK¹, Suneja U¹, Short KR², Palle S¹. J Okla State Med Assoc. 2018 Oct;111(8):806-811.

349.	NAFLD in children: new genes, new diagnostic modalities and new drugs
	Nobili V^1,2, Alisi A³, Valenti L^4,5, Miele L^6,7, Feldstein AE⁸, Alkhouri N⁹. Nat Rev Gastroenterol Hepatol. 2019 Jul 5. doi: 10.1038/s41575-019-0169-z. [Epub ahead of print]

350.	Depression is associated with non-alcoholic fatty liver disease among adults in the United States
	Kim D¹, Yoo ER², Li AA³, Tighe SP¹, Cholankeril G¹, Harrison SA⁴, Ahmed A¹. Aliment Pharmacol Ther. 2019 Jul 22. doi: 10.1111/apt.15395. [Epub ahead of print]

351.	Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
	Dibba P¹, Li AA², Cholankeril G³, Ali Khan M⁴, Kim D³, Ahmed A³. Nutr Metab Insights. 2019 May 13;12:1178638819847480. doi: 10.1177/1178638819847480. eCollection 2019.

352.	Risks of light and moderate alcohol use in fatty liver disease - follow-up of population cohorts
	Åberg F^1,2, Puukka P³, Salomaa V³, Männistö S³, Lundqvist A³, Valsta L³, Perola M³, Färkkilä M⁴, Jula A³. Hepatology. 2019 Jul 19. doi: 10.1002/hep.30864. [Epub ahead of print]

353.	Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners
	Casler K^1,2, Trees K¹, Bosak K¹. J Am Assoc Nurse Pract. 2019 Jun 27. doi: 10.1097/JXX.0000000000000223. [Epub ahead of print]

354.	Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic
	Debroy P¹, Lake JE, Malagoli A, Guaraldi G. J Frailty Aging. 2019;8(3):150-153. doi: 10.14283/jfa.2018.37.

355.	The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease
	Parker A¹, Kim Y¹. Metab Syndr Relat Disord. 2019 Jul 15. doi: 10.1089/met.2019.0038. [Epub ahead of print]

356.	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
	Rinella ME¹, Tacke F², Sanyal AJ³, Anstee QM⁴; participants of the AASLD/EASL Workshop. J Hepatol. 2019 Jul 9. pii: S0168-8278(19)30283-1. doi: 10.1016/j.jhep.2019.04.019. [Epub ahead of print]

357.	Liver sympathetic denervation reverses obesity-induced hepatic steatosis
	Hurr C^1,2, Simonyan H¹, Morgan DA³, Rahmouni K³, Young CN¹. J Physiol. 2019 Jul 6. doi: 10.1113/JP277994. [Epub ahead of print]

358.	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven nonalcoholic fatty liver disease
	Nobili V¹, Mantovani A², Cianfarani S³, Alisi A⁴, Mosca A⁵, Rita Sartorelli M⁶, Maffeis C⁷, Loomba R⁸, Byrne CD⁹, Targher G¹⁰. J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30395-2. doi: 10.1016/j.jhep.2019.06.023. [Epub ahead of print]

359.	Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn
	Kennedy L¹, Francis H^1,2, Alpini G^1,2. Hepatology. 2019 Jul 5. doi: 10.1002/hep.30843. [Epub ahead of print]

360.	Obesity and Liver Disease: The New Era of Liver Transplantation
	Marrero JA¹. Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854. [Epub ahead of print]

361.	The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
	Younossi ZM¹, Golabi P², de Avila L², Minhui Paik J², Srishord M², Fukui N³, Qiu Y⁴, Burns L⁴, Afendy A⁵, Nader F⁵. J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30393-9. doi: 10.1016/j.jhep.2019.06.021. [Epub ahead of print]

362.	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
	Rinella ME¹, Tacke F², Sanyal AJ³, Anstee QM⁴; participants of the AASLD/EASL Workshop. Hepatology. 2019 Jul 9. doi: 10.1002/hep.30782. [Epub ahead of print]

363.	Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment
	Molina-Molina E¹, Krawczyk M², Stachowska E³, Lammert F⁴, Portincasa P⁵. Clin Res Hepatol Gastroenterol. 2019 Jun 10. pii: S2210-7401(19)30095-6. doi: 10.1016/j.clinre.2019.04.005. [Epub ahead of print]

364.

Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease

Schwimmer JB¹, Johnson JS², Angeles JE³, Behling C⁴, Belt PH⁵, Borecki I⁶, Bross C⁷, Durelle J⁸, Goyal NP⁹, Hamilton G¹⁰, Holtz ML¹¹, Lavine JE¹², Mitreva M¹³, Newton KP¹⁴, Pan A¹⁵, Simpson PM¹⁶, Sirlin CB¹⁷, Sodergren E¹⁸, Tyagi R¹⁹, Yates KP²⁰, Weinstock G²¹, Salzman NH²². Gastroenterology. 2019 Jun 27. pii: S0016-5085(19)41037-8. doi: 10.1053/j.gastro.2019.06.028. [Epub ahead of print]

365.	A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
	Povsic M¹, Oliver L¹, Jiandani NR¹, Perry R¹, Bottomley J². Pharmacol Res Perspect. 2019 May 27;7(3):e00485. doi: 10.1002/prp2.485. eCollection 2019 Jun.

366.	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
	Newsome P^1,2, Francque S³, Harrison S⁴, Ratziu V⁵, Van Gaal L⁶, Calanna S⁷, Hansen M⁷, Linder M⁷, Sanyal A⁸. Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10.

367.	Fatty Liver and the Forensic Pathologist
	Milroy CM. Acad Forensic Pathol. 2018 Jun;8(2):296-310. doi: 10.1177/1925362118782061. Epub 2018 Jun 6.

368.	Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017
	Kim D¹, Adejumo AC², Yoo ER³, Iqbal U⁴, Li AA⁵, Pham EA⁶, Cholankeril G⁶, Glenn JS⁶, Ahmed A⁶. Gastroenterology. 2019 Jun 25. pii: S0016-5085(19)41033-0. doi: 10.1053/j.gastro.2019.06.026. [Epub ahead of print]

369.	Selective Trafficking of Fatty Acids in the Liver: Add Them2 to the List of Influencers
	Ginsberg HN¹. Hepatology. 2019 Jun 2. doi: 10.1002/hep.30800. [Epub ahead of print]

370.	Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
	Said A¹, Akhter A². Ann Hepatol. 2017 Jul - Aug;16(4):538-547. doi: 10.5604/01.3001.0010.0284.

371.	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis
	Liu L^1,2, Li P^3,4, Liu Y¹, Zhang Y¹. Dig Dis Sci. 2019 Jun 15. doi: 10.1007/s10620-019-05699-z. [Epub ahead of print]

372.	Psychotropic Medications are Associated with Increased Liver Disease Severity in Pediatric NAFLD
	Mouzaki M¹, Yodoshi T¹, Arce-Clachar AC¹, Bramlage K¹, Fei L², Hunsaker SL³, Xanthakos SA¹. J Pediatr Gastroenterol Nutr. 2019 May 18. doi: 10.1097/MPG.0000000000002401. [Epub ahead of print]

373.	Considering the links between NAFLD and insulin resistance: revisiting the role of protein kinase c
	Samuel VT¹, Petersen MC², Gassaway BM³, Vatner DF⁴, Rinehart J², Shulman GI⁵. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30829. [Epub ahead of print]

374.	Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review
	Lombardi R¹, Fargion S¹, Fracanzani AL². Dig Liver Dis. 2019 Jun 5. pii: S1590-8658(19)30594-8. doi: 10.1016/j.dld.2019.05.015. [Epub ahead of print]

375.	Macrophage Nourishment in NASH: A Novel Role for Ketone Bodies
	Torok NJ¹. Hepatology. 2019 May 20. doi: 10.1002/hep.30777. [Epub ahead of print]

376.	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum
	Cheung A¹, Neuschwander-Tetri BA², Kleiner DE³, Schabel E⁴, Rinella M⁵, Harrison S⁶, Ratziu V⁷, Sanyal AJ⁸, Loomba R⁹, Jeannin Megnien S¹⁰, Torstenson R¹¹, Miller V¹²; Liver Forum Case Definitions Working Group. Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672. [Epub ahead of print]

377.	Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature
	Green CH¹, Syn WK^2,3,4. Eur J Nutr. 2019 May 22. doi: 10.1007/s00394-019-01996-5. [Epub ahead of print]

378.	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fattyliver disease and potential therapeutic implications
	Jayakumar S¹, Loomba R^1,2. Aliment Pharmacol Ther. 2019 May 31. doi: 10.1111/apt.15314. [Epub ahead of print]

379.	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification
	Ioannou GN¹, Green P², Kerr KF³, Berry K². J Hepatol. 2019 May 27. pii: S0168-8278(19)30291-0. doi: 10.1016/j.jhep.2019.05.008. [Epub ahead of print]

380.	Is Trimming the Fat Enough? Fibroblast Growth Factor 21 as An Emerging Treatment for NAFLD
	Dushay J¹. Hepatology. 2019 May 28. doi: 10.1002/hep.30789. [Epub ahead of print]

381.	Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States
	Hirode G¹, Vittinghoff E², Wong RJ¹. J Clin Gastroenterol. 2019 May 22. doi: 10.1097/MCG.0000000000001229. [Epub ahead of print]

382.	A critical appraisal of the use of ultrasound in hepatic steatosis
	Ballestri S¹, Nascimbeni F², Lugari S³, Lonardo A², Francica G⁴. Expert Rev Gastroenterol Hepatol. 2019 May 29:1-15. doi: 10.1080/17474124.2019.1621164. [Epub ahead of print]

383.	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs
	Cook N¹, Geier A², Schmid A³, Hirschfield G⁴, Kautz A⁵, Schattenberg JM⁶, Balp MM¹. Front Med (Lausanne). 2019 Apr 3;6:61. doi: 10.3389/fmed.2019.00061. eCollection 2019.

384.	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis Score and Cognitive Function in Middle-Aged Adults: The Framingham Study
	Weinstein G¹, Davis-Plourde K^2,3, Himali JJ^2,3,4, Zelber-Sagi S^1,5, Beiser AS^2,3,4, Seshadri S^3,4,6. Liver Int. 2019 Jun 2. doi: 10.1111/liv.14161. [Epub ahead of print]

385.

The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content

Gepner Y¹, Shelef I², Komy O³, Cohen N³, Schwarzfuchs D⁴, Bril N³, Rein M³, Serfaty D³, Kenigsbuch S³, Zelicha H³, Yaskolka Meir A³, Tene L³, Bilitzky A³, Tsaban G³, Chassidim Y², Sarusy B⁵, Ceglarek U⁶, Thiery J⁶, Stumvoll M⁶, Blüher M⁶, Stampfer MJ⁷, Rudich A³, Shai I⁸. J Hepatol. 2019 May 8. pii: S0168-8278(19)30274-0. doi: 10.1016/j.jhep.2019.04.013. [Epub ahead of print]

386.	Fatty liver disease in persons with HIV infection
	Seth A¹, Sherman KE¹. Top Antivir Med. 2019 May;27(2):75-82.

387.	Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003?2014
	Christensen K¹, Lawler T², Mares J³. Nutrients. 2019 May 17;11(5). pii: E1101. doi: 10.3390/nu11051101.

388.	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liverdisease: a qualitative study
	Hallsworth K^1,2, Dombrowski SU³, McPherson S², Anstee QM^1,2, Avery L⁴. Transl Behav Med. 2019 May 23. pii: ibz080. doi: 10.1093/tbm/ibz080. [Epub ahead of print]

389.	A Structured Literature Review of the Epidemiology and Disease Burden of Non-AlcoholicSteatohepatitis (NASH)
	Povsic M¹, Wong OY², Perry R², Bottomley J³. Adv Ther. 2019 May 7. doi: 10.1007/s12325-019-00960-3. [Epub ahead of print]

390.	Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study
	De Silva NMG^1,2,3, Borges MC^1,2, Hingorani A^4,5, Engmann J⁴, Shah T⁴, Zhang X^6,7,8, Luan J⁶, Langenberg C⁶, Wong A⁹, Kuh D⁹, Chambers JC^3,10,11, Zhang W^12,13, Jarvelin MR^12,14,15, Sebert S¹⁴, Auvinen J^14,16; UCLEB consortium, Gaunt TR^1,2, Lawlor DA^17,2. Diabetes. 2019 May 14. pii: db181048. doi: 10.2337/db18-1048. [Epub ahead of print]

391.	Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease
	Gan D¹, Wang L¹, Jia M¹, Ru Y¹, Ma Y², Zheng W³, Zhao X¹, Yang F¹, Wang T⁴, Mu Y⁵, Zhu S⁶. Clin Nutr. 2019 Apr 25. pii: S0261-5614(19)30199-2. doi: 10.1016/j.clnu.2019.04.023. [Epub ahead of print]

392.	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis
	Mantovani A¹, Lonardo A², Vinco G¹, Zoppini G¹, Lippi G³, Bonora E¹, Loomba R⁴, Tilg H⁵, Byrne CD⁶, Fabbri L⁷, Targher G⁸. Diabetes Metab. 2019 May 5. pii: S1262-3636(19)30068-0. doi: 10.1016/j.diabet.2019.04.008. [Epub ahead of print]

393.	Diagnosis and management of non-alcoholic fatty liver disease
	Jennison E¹, Patel J², Scorletti E³, Byrne CD⁴. Postgrad Med J. 2019 May 13. pii: postgradmedj-2018-136316. doi: 10.1136/postgradmedj-2018-136316. [Epub ahead of print]

394.	Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis
	Zhou F^1,2,3,4, Zhou J^1,2,3, Wang W^1,2,3, Zhang XJ^1,2,3, Ji YX^1,2,3, Zhang P^1,2,3, She ZG^1,2,3, Zhu L^1,2,3, Cai J^1,5,2, Li H^1,2,3. Hepatology. 2019 May 9. doi: 10.1002/hep.30702. [Epub ahead of print]

395.

Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study

Haldar D¹, Kern B², Hodson J³, James Armstrong M⁴, Adam R⁵, Berlakovich G⁶, Fritz J⁷, Feurstein B⁸, Popp W⁸, Karam V⁵, Muiesan P⁹, O'Grady J¹⁰, Jamieson N¹¹, Wigmore SJ¹², Pirenne J¹³, Ali Malek-Hosseini S¹⁴, Hidalgo E¹⁵, Tokat Y¹⁶, Paul A¹⁷, Pratschke J¹⁸, Bartels M¹⁹, Trunecka P²⁰, Settmacher U²¹, Pinzani M²², Duvoux C²³, Noel Newsome P²⁴, Schneeberger S⁸; European Liver, Intestine Transplant Association (ELITA). J Hepatol. 2019 May 6. pii: S0168-8278(19)30272-7. doi: 10.1016/j.jhep.2019.04.011. [Epub ahead of print]

396.	Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
	Berger A^1,2, Shili S³, Zuberbuhler F^1,2, Hiriart JB³, Lannes A^1,2, Chermak F³, Hunault G², Foucher J³, Oberti F^1,2, Fouchard-Hubert I^1,2, Cales P^1,2, de Ledinghen V^3,4, Boursier J^1,2. Clin Transl Gastroenterol. 2019 Apr;10(4):e00023. doi: 10.14309/ctg.0000000000000023.

397.	Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
	Wong T^1,2,3, Wong RJ^1,2,3, Gish RG^1,2,3. Gastroenterol Hepatol (N Y). 2019 Feb;15(2):83-89.

398.

New sequential combinations of noninvasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD

Boursier J¹, Guillaume M², Leroy V³, Irlès M⁴, Roux M⁵, Lannes A⁶, Foucher J⁴, Zuberbuhler F⁶, Delabaudière C⁷, Barthelon J⁸, Michalak S⁹, Hiriart JB⁴, Peron JM², Gerster T⁸, Le Bail B¹⁰, Riou J¹¹, Hunault G⁵, Merrouche W⁴, Oberti F⁶, Pelade L⁸, Fouchard I⁶, Bureau C², Calès P⁶, de Ledinghen V¹². J Hepatol. 2019 May 15. pii: S0168-8278(19)30284-3. doi: 10.1016/j.jhep.2019.04.020. [Epub ahead of print]

399.	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
	Alexander M¹, Loomis AK², van der Lei J³, Duarte-Salles T⁴, Prieto-Alhambra D⁵, Ansell D⁶, Pasqua A⁷, Lapi F⁷, Rijnbeek P³, Mosseveld M³, Waterworth DM⁸, Kendrick S⁹, Sattar N¹⁰, Alazawi W¹¹. BMC Med. 2019 May 20;17(1):95. doi: 10.1186/s12916-019-1321-x.

400.	The liver as an endocrine organ - linking NAFLD and insulin resistance
	Watt MJ¹, Miotto PM¹, De Nardo W¹, Montgomery MK¹. Endocr Rev. 2019 Apr 25. pii: er.2019-00034. doi: 10.1210/er.2019-00034. [Epub ahead of print]

401.	Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014
	Kim D¹, Cholankeril G¹, Li AA², Kim W³, Tighe SP¹, Hameed B⁴, Kwo PY¹, Harrison SA⁵, Younossi ZM⁶, Ahmed A¹. Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]

402.	Understanding Environmental Contaminants
	Armstrong LE¹, Guo GL^2,3,4. Curr Environ Health Rep. 2019 May 14. doi: 10.1007/s40572-019-00231-x. [Epub ahead of print]

403.	Increased Risk of Death in First Year After Liver Transplantation Among Patients with Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies
	Nagai S¹, Collins K², Chau LC², Safwan M², Rizzari M², Yoshida A², Abouljoud MS², Moonka D³. Clin Gastroenterol Hepatol. 2019 Apr 17. pii: S1542-3565(19)30423-9. doi: 10.1016/j.cgh.2019.04.033. [Epub ahead of print]

404.	Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review
	Besutti G^1,2, Valenti L^3,4, Ligabue G⁵, Bassi MC⁶, Pattacini P², Guaraldi G⁷, Giorgi Rossi P⁸. Liver Int. 2019 Apr 10. doi: 10.1111/liv.14118. [Epub ahead of print]

405.	Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery
	Udelsman BV¹, Corey KE², Lindvall C³, Gee DW⁴, Meireles OR⁴, Hutter MM⁴, Chang DC⁴, Witkowski ER⁴. Surg Obes Relat Dis. 2019 Mar 20. pii: S1550-7289(19)30050-4. doi: 10.1016/j.soard.2019.01.035. [Epub ahead of print]

406.	Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial)
	Ajmera VH^1,2, Cachay E³, Ramers C⁴, Vodkin I², Bassirian S¹, Singh S¹, Mangla N¹, Bettencourt R¹, Aldous JL⁵, Park D⁵, Lee D³, Blanchard J³, Mamidipalli A⁶, Boehringer A⁶, Aslam S⁷, Leinhard OD^8,9, Richards L¹, Sirlin C⁶, Loomba R^1,2,10. Hepatology. 2019 Apr 23. doi: 10.1002/hep.30674. [Epub ahead of print]

407.	A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries
	Kapoor N^1,2, Audsley J³, Rupali P⁴, Sasadeusz J⁵, Paul TV¹, Thomas N¹, Lewin SR^3,6. AIDS. 2019 Jun 1;33(7):1105-1115. doi: 10.1097/QAD.0000000000002161.

408.	Environmental risk factors for liver cancer and nonalcoholic fatty liver disease
	VoPham T¹. Curr Epidemiol Rep. 2019 Mar;6(1):50-66. doi: 10.1007/s40471-019-0183-2. Epub 2019 Feb 6.

409.	Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease
	Simon TG¹, Henson J², Osganian S³, Masia R⁴, Chan AT⁵, Chung RT⁶, Corey KE⁷. Clin Gastroenterol Hepatol. 2019 May 8. pii: S1542-3565(19)30493-8. doi: 10.1016/j.cgh.2019.04.061. [Epub ahead of print]

410.	Prevalence of nocturia and fecal and urinary incontinence and the association to childhood obesity: a study of 6803 Danish school children
	Warner TC¹, Baandrup U², Jacobsen R³, Bøggild H⁴, Aunsholt Østergaard PS⁵, Hagstrøm S⁶. J Pediatr Urol. 2019 Feb 15. pii: S1477-5131(19)30042-7. doi: 10.1016/j.jpurol.2019.02.004. [Epub ahead of print]

411.	Helicobacter pylori infection and NAFLD
	Mantovani A¹, Turino T¹, Altomari A¹, Lonardo A², Zoppini G¹, Valenti L³, Tilg H⁴, Byrne CD⁵, Targher G⁶. Metabolism. 2019 Apr 29. pii: S0026-0495(19)30084-8. doi: 10.1016/j.metabol.2019.04.012. [Epub ahead of print]

412.	Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution
	Alferink LJM¹, Trajanoska K^2,3, Erler NS⁴, Schoufour JD^2,3, de Knegt RJ¹, Ikram MA², Janssen HLA^1,5, Franco OH^2,6, Metselaar HJ¹, Rivadeneira F^2,3, Darwish Murad S¹. J Bone Miner Res. 2019 May 10. doi: 10.1002/jbmr.3713. [Epub ahead of print]

413.	Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis
	Vitaglione P^1,2, Mazzone G³, Lembo V³, D'Argenio G³, Rossi A³, Guido M⁴, Savoia M⁵, Salomone F⁶, Mennella I¹, De Filippis F^1,2, Ercolini D^1,2, Caporaso N^2,3, Morisco F^2,3. J Nutr Sci. 2019 Apr 22;8:e15. doi: 10.1017/jns.2019.10. eCollection 2019.

414.	Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis
	Do A¹, Kuszewski EJ², Mehal WZ^1,2. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30658. [Epub ahead of print]

415.	Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation
	Tokodai K¹, Karadagi A¹, Kjaernet F¹, Romano A¹, Ericzon BG¹, Nowak G¹. Scand J Gastroenterol. 2019 Apr 18:1-7. doi: 10.1080/00365521.2019.1577484. [Epub ahead of print]

416.	From NASH to HCC: current concepts and future challenges
	Anstee QM^1,2, Reeves HL^3,4,5, Kotsiliti E⁶, Govaere O⁷, Heikenwalder M⁸. Nat Rev Gastroenterol Hepatol. 2019 Apr 26. doi: 10.1038/s41575-019-0145-7. [Epub ahead of print]

417.	Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
	Alkhouri N^1,2, Lawitz E^1,2, Noureddin M³. Hepatol Commun. 2019 Mar 28;3(5):605-613. doi: 10.1002/hep4.1342. eCollection 2019 May.

418.	Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial
	Corey KE¹, Wilson LA², Altinbas A¹, Yates KP², Kleiner DE³, Chung RT¹, Krauss RM⁴, Chalasani N⁵; NASH Clinical Research Network. Aliment Pharmacol Ther. 2019 May;49(9):1205-1213. doi: 10.1111/apt.15216. Epub 2019 Mar 10.

419.	Resolving inflammation in nonalcoholic steatohepatitis
	Spite M. J Clin Invest. 2019 Mar 11;130:1524-1526. doi: 10.1172/JCI127583. eCollection 2019 Mar 11.

420.	Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease
	Mills PJ¹, Caussy C², Loomba R³. Clin Gastroenterol Hepatol. 2019 Apr 4. pii: S1542-3565(19)30361-1. doi: 10.1016/j.cgh.2019.03.045. [Epub ahead of print]

421.	NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study
	Axley P¹, Ahmed Z², Arora S³, Haas A⁴, Kuo YF⁴, Kamath PS⁵, Singal AK⁶. Liver Transpl. 2019 May;25(5):695-705. doi: 10.1002/lt.25443.

422.	Past, present and future perspectives in nonalcoholic fatty liver disease
	Sanyal AJ¹. Nat Rev Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1038/s41575-019-0144-8. [Epub ahead of print]

423.	Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department
	Likhitsup A^1,2, Dundulis J¹, Ansari S³, El-Halawany H¹, Michelson R¹, Hutton C⁴, Kennedy K⁵, Helzberg JH^1,2, Chhabra R^1,2. Ann Gastroenterol. 2019 May-Jun;32(3):283-286. doi: 10.20524/aog.2019.0371. Epub 2019 Mar 15.

424.	Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
	Szanto KB^1,2, Li J^2,3, Cordero P², Oben JA^2,4. Diabetes Metab Syndr Obes. 2019 Mar 19;12:357-367. doi: 10.2147/DMSO.S182331. eCollection 2019.

425.

A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease

Ma J^1,2, Nano J^3,4,5, Ding J⁶, Zheng Y⁷, Hennein R¹, Liu C^1,8, Speliotes EK⁹, Huan T¹, Song C^1,10, Mendelson MM^1,11, Joehanes R¹, Long MT¹², Liang L^13,14, Smith JA¹⁵, Reynolds LM⁶, Ghanbari M^3,16, Muka T³, van Meurs JBJ^3,17, Alferink LJM¹⁸, Franco OH³, Dehghan A^3,19, Ratliff S¹⁵, Zhao W¹⁵, Bielak L¹⁵, Kardia SLR¹⁵, Peyser PA¹⁵, Ning H⁷, VanWagner LB^7,20, Lloyd-Jones DM⁷, Carr JJ²¹, Greenland P⁷, Lichtenstein AH²², Hu FB²³, Liu Y⁶, Hou L⁷, Darwish Murad S¹⁸, Levy D²⁴. Diabetes. 2019 May;68(5):1073-1083. doi: 10.2337/DB18-1193. Epub 2019 Apr 1.

426.	The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials
	White CM¹, Lee JY². Pharm Pract (Granada). 2019 Jan-Mar;17(1):1350. doi: 10.18549/PharmPract.2019.1.1350. Epub 2019 Mar 4.

427.	A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC)
	Dhanasekaran R¹, Felsher DW². Hepatology. 2019 Apr 8. doi: 10.1002/hep.30649. [Epub ahead of print]

428.	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
	Caussy C^1,2, Tripathi A^3,4,5,6, Humphrey G⁴, Bassirian S¹, Singh S¹, Faulkner C¹, Bettencourt R^1,7, Rizo E¹, Richards L¹, Xu ZZ⁴, Downes MR⁸, Evans RM⁸, Brenner DA^1,9, Sirlin CB¹⁰, Knight R^3,4,11,12, Loomba R^13,14,15. Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.

429.	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
	Iqbal U¹, Perumpail BJ², Akhtar D³, Kim D⁴, Ahmed A⁵. Medicines (Basel). 2019 Mar 18;6(1). pii: E41. doi: 10.3390/medicines6010041.

430.	Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States
	Kim D¹, Yoo ER², Li AA³, Cholankeril G¹, Tighe SP¹, Kim W⁴, Harrison SA⁵, Ahmed A¹. Liver Int. 2019 Mar 29. doi: 10.1111/liv.14110. [Epub ahead of print]

431.	Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis
	Lin B^1,2,3, Ma Y^1,2, Wu S⁴, Liu Y⁵, Liu L⁶, Wu L⁷. OMICS. 2019 Apr;23(4):181-189. doi: 10.1089/omi.2019.0035. Epub 2019 Mar 30.

432.	The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials
	Sanyal AJ¹, Harrison SA², Ratziu V³, Abdelmalek MF⁴, Diehl AM⁴, Caldwell S⁵, Shiffman ML⁶, Schall RA⁷, Jia C⁷, McColgan B⁷, Djedjos CS⁷, McHutchison JG⁷, Subramanian GM⁷, Myers RP⁷, Younossi Z⁸, Muir AJ⁴, Afdhal NH⁹, Bosch J^10,11, Goodman Z⁸. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print]

433.	Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma
	Hester CA¹, Rich NE², Singal AG², Yopp AC¹. J Natl Compr Canc Netw. 2019 Apr 1;17(4):322-329. doi: 10.6004/jnccn.2018.7105.

434.	Metabolic Targets in Nonalcoholic Fatty Liver Disease
	Esler WP¹, Bence KK². Cell Mol Gastroenterol Hepatol. 2019 Apr 17. pii: S2352-345X(19)30046-3. doi: 10.1016/j.jcmgh.2019.04.007. [Epub ahead of print]

435.	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
	Golabi P¹, Paik J¹, Reddy R², Bugianesi E³, Trimble G², Younossi ZM^4,5. BMC Gastroenterol. 2019 Apr 16;19(1):56. doi: 10.1186/s12876-019-0972-6.

436.	The influence of dietary fatty acids on liver fat content and metabolism
	Hodson L¹, Rosqvist F¹, Parry SA¹. Proc Nutr Soc. 2019 Apr 3:1-12. doi: 10.1017/S0029665119000569. [Epub ahead of print]

437.	Contemporary Epidemiology of Cirrhosis
	Baki JA¹, Tapper EB^2,3. Curr Treat Options Gastroenterol. 2019 Apr 4. doi: 10.1007/s11938-019-00228-3. [Epub ahead of print]

438.	Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments
	Roeb E¹, Geier A². Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9.

439.	The Circadian Clock and Liver Function in Health and Disease
	Mukherji A¹, Bailey SM², Staels B³, Baumert TF⁴. J Hepatol. 2019 Mar 28. pii: S0168-8278(19)30191-6. doi: 10.1016/j.jhep.2019.03.020. [Epub ahead of print]

440.	Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients
	Danford CJ¹, Iriana S¹, Shen C², Curry MP¹, Lai M¹. Liver Int. 2019 Feb 27. doi: 10.1111/liv.14080. [Epub ahead of print]

441.	Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
	Yabut JM^1,2, Crane JD³, Green AE^1,2, Keating DJ⁴, Khan WI^2,5,6, Steinberg GR^1,2,6,7. Endocr Rev. 2019 Mar 22. pii: er.2018-00283. doi: 10.1210/er.2018-00283. [Epub ahead of print]

442.	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
	Srivastava A¹, Gailer R¹, Tanwar S¹, Trembling P¹, Parkes J², Rodger A³, Suri D⁴, Thorburn D¹, Sennett K⁵, Morgan S⁶, Tsochatzis EA⁷, Rosenberg W⁸. J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30227-2. doi: 10.1016/j.jhep.2019.03.033. [Epub ahead of print]

443.	Obstructive Sleep Apnea and the Liver
	Parikh MP¹, Gupta NM¹, McCullough AJ². Clin Liver Dis. 2019 May;23(2):363-382. doi: 10.1016/j.cld.2019.01.001.

444.	Nonalcoholic Fatty Liver Disease and Obesity Treatment
	Brunner KT¹, Henneberg CJ², Wilechansky RM³, Long MT⁴. Curr Obes Rep. 2019 Apr 3. doi: 10.1007/s13679-019-00345-1. [Epub ahead of print]

445.	Fatty Liver Disease and Gut Microbiota: A Comprehensive Update
	Campo L¹, Eiseler S¹, Apfel T¹, Pyrsopoulos N¹. J Clin Transl Hepatol. 2019 Mar 28;7(1):56-60. doi: 10.14218/JCTH.2018.00008. Epub 2018 Dec 28.

446.	Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
	Hassan I¹, Gane E¹. Intern Med J. 2019 Mar 25. doi: 10.1111/imj.14304. [Epub ahead of print]

447.	Sex Differences in NAFLD: State of the Art and Identification of Research Gaps
	Lonardo A¹, Nascimbeni F¹, Ballestri S², Fairweather D³, Win S⁴, Than TA⁴, Abdelmalek MF⁵, Suzuki A^5,6. Hepatology. 2019 Mar 29. doi: 10.1002/hep.30626. [Epub ahead of print]

448.	Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA
	Wijarnpreecha K^1,2, Kim D³, Raymond P¹, Scribani M⁴, Ahmed A³. Eur J Gastroenterol Hepatol. 2019 Mar 18. doi: 10.1097/MEG.0000000000001397. [Epub ahead of print]

449.

Obesity in the critically ill: a narrative review

Schetz M¹, De Jong A², Deane AM^3,4, Druml W⁵, Hemelaar P⁶, Pelosi P^7,8, Pickkers P^6,9, Reintam-Blaser A^10,11, Roberts J^12,13,14,15, Sakr Y¹⁶, Jaber S².

Intensive Care Med. 2019 Mar 19. doi: 10.1007/s00134-019-05594-1. [Epub ahead of print]

450.	Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype
	Martín Mateos R¹, Allen AM². Rev Esp Enferm Dig. 2019 Mar 28;111:253-255. doi: 10.17235/reed.2019.6269/2019. [Epub ahead of print]

451.	Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography
	Yin Z¹, Murphy MC¹, Li J¹, Glaser KJ¹, Mauer AS², Mounajjed T³, Therneau TM⁴, Liu H⁴, Malhi H², Manduca A^1,5, Ehman RL¹, Yin M⁶. Eur Radiol. 2019 Mar 18. doi: 10.1007/s00330-019-06076-0. [Epub ahead of print]

452.	Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes
	Barb D¹, Bril F¹, Kalavalapalli S¹, Cusi K^1,2. J Clin Endocrinol Metab. 2019 Mar 8. pii: jc.2018-02414. doi: 10.1210/jc.2018-02414. [Epub ahead of print]

453.	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis
	Moore JB¹. Proc Nutr Soc. 2019 Mar 29:1-15. doi: 10.1017/S0029665119000570. [Epub ahead of print]

454.	Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems
	Hawksworth DJ¹, Burnett AL². Sex Med Rev. 2019 Mar 19. pii: S2050-0521(19)30005-8. doi: 10.1016/j.sxmr.2019.01.002. [Epub ahead of print]

455.	Sarcopenic obesity in fatty liver
	Merli M¹, Lattanzi B, Aprile F. JCurr Opin Clin Nutr Metab Care. 2019 Mar 18. doi: 10.1097/MCO.0000000000000558. [Epub ahead of print]

456.	MR Imaging: A Personalized approach to understanding fatty liver disease
	Barnekow K¹, Shyken P², Ito J², Deng J², Mohammad S³, Fishbein M⁴. J Pediatr Gastroenterol Nutr. 2019 Mar 5. doi: 10.1097/MPG.0000000000002316. [Epub ahead of print]

457.	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?
	Dong TS^1,2, Jacobs JP^1,2,3. Exp Biol Med (Maywood). 2019 Mar 14:1535370219836739. doi: 10.1177/1535370219836739. [Epub ahead of print]

458.	Hepatitis B and C virus infection as a risk factor for Parkinson
	Goldstein L¹, Fogel-Grinvald H², Steiner I³. J Neurol Sci. 2019 Mar 15;398:138-141. doi: 10.1016/j.jns.2019.01.012. Epub 2019 Jan 11.

459.	The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
	Carulli L¹, Zanca G², Schepis F³, Villa E⁴. Metabolites. 2019 Feb 1;9(2). pii: E25. doi: 10.3390/metabo9020025.

460.	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis
	Klebanoff MJ¹, Corey KE^2,3, Samur S^4,5, Choi JG⁵, Kaplan LM^2,3, Chhatwal J^2,3,5, Hur C⁶. JAMA Netw Open. 2019 Feb 1;2(2):e190047. doi: 10.1001/jamanetworkopen.2019.0047.

461.	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume
	Abeles RD¹, Mullish BH¹, Forlano R¹, Kimhofer T², Adler M¹, Tzallas A³, Giannakeas N³, Yee M⁴, Mayet J⁵, Goldin RD⁶, Thursz MR¹, Manousou P¹. Aliment Pharmacol Ther. 2019 Mar 5. doi: 10.1111/apt.15192. [Epub ahead of print]

462.	An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease(NAFLD) associated with obesity
	Nistal E¹, Sáenz de Miera LE², Ballesteros Pomar M³, Sánchez Campos S², García Mediavilla MV², Álvarez Cuenllas B⁴, Linares P⁵, Olcoz JL³, Arias Loste MT⁶, García Lobo JM⁷, Crespo J⁸, González Gallego J², Jorquera Plaza F⁹. Rev Esp Enferm Dig. 2019 Feb 27;111. doi: 10.17235/reed.2019.6068/2018. [Epub ahead of print]

463.	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease(NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study
	Vilar-Gomez E¹, Athinarayanan SJ², Adams RN², Hallberg SJ^2,3, Bhanpuri NH², McKenzie AL², Campbell WW⁴, McCarter JP^2,5, Phinney SD², Volek JS^2,6, Chalasani N¹. BMJ Open. 2019 Feb 25;9(2):e023597. doi: 10.1136/bmjopen-2018-023597.

464.	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLDwithout cirrhosis
	Bengtsson B^1,2, Stål P^1,2, Wahlin S^1,2, Björkström NK³, Hagström H^1,4. Liver Int. 2019 Mar 4. doi: 10.1111/liv.14087. [Epub ahead of print]

465.	Development and relative validation of a short food frequency questionnaire for assessing dietary intakes of non-alcoholic fatty liver disease patients
	Bredin C¹, Naimimohasses S^2,3, Norris S^2,3, Wright C⁴, Hancock N⁵, Hart K¹, Moore JB^6,7. Eur J Nutr. 2019 Feb 25. doi: 10.1007/s00394-019-01926-5. [Epub ahead of print]

466.	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis
	Regev A¹, Palmer M², Avigan MI³, Dimick-Santos L³, Treem WR⁴, Marcinak JF⁵, Seekins D⁶, Krishna G⁷, Anania FA³, Freston JW⁸, Lewis JH⁹, Sanyal AJ¹⁰, Chalasani N¹. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13.

467.	Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review
	Stahl EP¹, Dhindsa DS², Lee SK¹, Sandesara PB², Chalasani NP³, Sperling LS⁴. J Am Coll Cardiol. 2019 Mar 5;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050.

468.	Current treatment options for nonalcoholic fatty liver disease
	Shetty A^1,2, Syn WK^3,4,5,2. Curr Opin Gastroenterol. 2019 Feb 21. doi: 10.1097/MOG.0000000000000528. [Epub ahead of print]

469.	Population Management of Nonalcoholic Fatty Liver Disease
	Puri P¹, Fuchs M¹. Fed Pract. 2019 Feb;36(2):72-82.

470.	Assessing liver fibrosis without biopsy in patients with HCV or NAFLD
	Singh T¹, Allende DS^2,3, McCullough AJ^4,5. Cleve Clin J Med. 2019 Mar;86(3):179-186. doi: 10.3949/ccjm.86a.17118.

471.	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?
	Glass LM¹, Hunt CM¹, Fuchs M¹, Su GL¹. Fed Pract. 2019 Feb;36(2):64-71.

472.	NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
	Harrison SA^1,2, Rossi SJ³, Paredes AH⁴, Trotter JF⁵, Bashir MR⁶, Guy CD⁷, Banerjee R⁸, Jaros MJ⁹, Owers S², Baxter BA³, Ling L³, DePaoli AM³. Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590. [Epub ahead of print]

473.	Evidence of bias during liver transplant evaluation of nonalcoholic steatohepatitis cirrhosis patients
	Danford CJ¹, Iriana S¹, Shen C², Curry MP¹, Lai M¹. Liver Int. 2019 Feb 27. doi: 10.1111/liv.14080. [Epub ahead of print]

474.	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
	Perumpail BJ¹, Li AA², John N³, Sallam S⁴, Shah ND⁵, Kwong W⁶, Cholankeril G⁷, Kim D⁸, Ahmed A⁹. Diseases. 2019 Feb 25;7(1). pii: E27. doi: 10.3390/diseases7010027.

475.	Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
	Parker HM^1,2, Cohn JS³, O'Connor HT^4,5, Garg ML⁶, Caterson ID⁷, George J⁸, Johnson NA^9,10,11. Nutrients. 2019 Feb 23;11(2). pii: E475. doi: 10.3390/nu11020475.

476.	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times
	Gitto S¹, Marra F¹, De Maria N², Bihl F³, Villa E², Andreone P⁴, Burra P⁵. Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):173-178. doi: 10.1080/17474124.2019.1551132. Epub 2018 Nov 30.

477.	Mini-review: end-points for drug treatment in NASH
	Adams LA^1,2. Hepatol Int. 2019 Feb 19. doi: 10.1007/s12072-019-09935-6. [Epub ahead of print]

478.	Health and Economic Burden of Nonalcoholic Fatty Liver Disease in the United States and Its Impact on Veterans
	Shetty A¹, Syn WK¹. Fed Pract. 2019 Jan;36(1):14-19.

479.	Correlation Between Adiponectin Gene rs1501299 Polymorphism and Nonalcoholic Fatty LiverDisease Susceptibility: A Systematic Review and Meta-Analysis
	Liu J¹, Xing J², Wang B², Wei C³, Yang R², Zhu Y², Qiu H². Med Sci Monit. 2019 Feb 8;25:1078-1086. doi: 10.12659/MSM.912737.

480.	Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study
	Ren XY^1,2, Shi D^1,2, Ding J³, Cheng ZY^2,4, Li HY³, Li JS², Pu HQ³, Yang AM^2,5, He CL², Zhang JP², Ma YB², Zhang YW⁴, Zheng TZ⁵, Bai YN⁶, Cheng N⁷. Lipids Health Dis. 2019 Feb 11;18(1):47. doi: 10.1186/s12944-019-0984-9.

481.	Identifying and Treating Nonalcoholic Fatty Liver Disease
	Hunt CM¹, Turner MJ¹, Gifford EJ¹, Britt RB¹, Su GL¹. Fed Pract. 2019 Jan;36(1):20-29.

482.	Non-alcoholic fatty liver disease: prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study
	Croci I¹, Coombes JS², Sandbakk SB³, Keating SE², Nauman J⁴, Macdonald GA⁵, Wisloff U⁶. Prog Cardiovasc Dis. 2019 Feb 20. pii: S0033-0620(19)30033-7. doi: 10.1016/j.pcad.2019.01.005. [Epub ahead of print]

483.	Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis
	Younossi ZM¹, Stepanova M², Anstee QM³, Lawitz EJ⁴, Wong VW⁵, Romero-Gomez M⁶, Kersey K⁷, Li G⁷, Subramanian GM⁷, Myers RP⁷, Djedjos CS⁷, Okanoue T⁸, Trauner M⁹, Goodman Z¹⁰, Harrison SA¹¹. Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024. [Epub ahead of print]

484.	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
	Pavlik L¹, Regev A², Ardayfio PA³, Chalasani NP⁴. Drug Saf. 2019 Feb 14. doi: 10.1007/s40264-018-00790-2. [Epub ahead of print]

485.	Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
	Mandal A¹, Bhattarai B¹, Kafle P¹, Khalid M¹, Jonnadula SK¹, Lamicchane J², Kanth R³, Gayam V¹. Cureus. 2018 Nov 23;10(11):e3626. doi: 10.7759/cureus.3626.

486.	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
	Golabi P¹, Paik J¹, Fukui N², Locklear CT², de Avilla L¹, Younossi ZM^1,2. Clin Diabetes. 2019 Jan;37(1):65-72. doi: 10.2337/cd18-0026.

487.	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
	Eddowes PJ¹, Sasso M², Allison M³, Tsochatzis E⁴, Anstee QM⁵, Sheridan D⁶, Guha IN⁷, Cobbold JF⁸, Deeks JJ⁹, Paradis V¹⁰, Bedossa P¹⁰, Newsome PN¹¹. Gastroenterology. 2019 Jan 25. pii: S0016-5085(19)30105-2. doi: 10.1053/j.gastro.2019.01.042. [Epub ahead of print]

488.	Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic FattyLiver Disease in Midlife
	Sarkar M¹, VanWagner LB²,³, Terry JG⁴, Carr JJ⁴, Rinella M², Schreiner PJ⁵, Lewis CE⁶, Terrault N¹; Coronary Artery Risk Development in Young Adults (CARDIA) Cohort. Am J Gastroenterol. 2019 Feb 4. doi: 10.14309/ajg.0000000000000138. [Epub ahead of print

489.	Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum
	Fitzpatrick E¹. Proc Nutr Soc. 2019 Feb 8:1-10. doi: 10.1017/S0029665118002914. [Epub ahead of print]

490.	Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer
	Divella R¹, Mazzocca A², Daniele A¹, Sabbà C², Paradiso A³. Int J Biol Sci. 2019 Jan 1;15(3):610-616. doi: 10.7150/ijbs.29599. eCollection 2019.

491.	American ancestry is a risk factor for suspected non-alcoholic fatty liver disease in Hispanic/Latino adults
	Kallwitz ER¹, Tayo BO², Kuniholm MH³, Cai J⁴, Daviglus M⁵, Cooper RS², Cotler SJ⁶. Clin Gastroenterol Hepatol. 2019 Feb 8. pii: S1542-3565(19)30145-4. doi: 10.1016/j.cgh.2019.02.007. [Epub ahead of print]

492.	Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation
	Wu EM¹, Wong LL¹, Hernandez BY², Ji JF³, Jia W², Kwee SA², Kalathil S⁴. Hepatoma Res. 2018;4. pii: 66. doi: 10.20517/2394-5079.2018.87. Epub 2018 Oct 18.

493.	Non-alcoholic fatty liver disease (NAFLD), active component, U.S. Armed Forces, 2000-2017
	Williams VF, Taubman SB, Stahlman S. MSMR. 2019 Jan;26(1):2-11.

494.

Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States

Shapiro WL¹,²,³, Yu EL¹,³, Arin JC¹, Murray KF⁴, Ali S⁵, Desai NK⁶, Xanthakos SA⁷,⁸, Lin HC⁹, Alkhouri N¹⁰,¹¹, Abdou R¹², Abrams SH¹³,¹⁴,¹⁵,¹⁶, Butler MW¹⁷, Faasse SA¹⁸,¹⁹, Gillis LA²⁰, Hadley TA¹⁸, Jain AK²¹, Kavan M²², Kordy K²³, Lee P²⁴, Panganiban J²⁵, Pohl JF²², Potter C²⁶, Rudolph B²⁷, Sundaram SS²⁸,²⁹, Joshi S¹,³⁰, Proudfoot JA³¹, Goyal NP¹,³, Harlow KE¹,³, Newton KP¹,³, Schwimmer JB¹,³. J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):182-189. doi: 10.1097/MPG.0000000000002194.

495.	Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial
	Schwimmer JB¹,², Ugalde-Nicalo P¹, Welsh JA³,⁴,⁵, Angeles JE¹, Cordero M³, Harlow KE¹,², Alazraki A⁶, Durelle J¹, Knight-Scott J⁶, Newton KP¹,², Cleeton R³, Knott C⁷, Konomi J³, Middleton MS⁸, Travers C⁹, Sirlin CB⁸, Hernandez A³, Sekkarie A⁵, McCracken C⁴,⁹, Vos MB³,⁴,⁵. JAMA. 2019 Jan 22;321(3):256-265. doi: 10.1001/jama.2018.20579.

496.	Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis
	Dornas W¹, Lagente V². Pharmacol Res. 2019 Jan 15;141:418-428. doi: 10.1016/j.phrs.2019.01.026. [Epub ahead of print]

497.	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis
	Mantovani A¹, Dauriz M¹, Sandri D¹, Bonapace S², Zoppini G¹, Tilg H³, Byrne CD⁴,⁵, Targher G¹. Liver Int. 2019 Jan 18. doi: 10.1111/liv.14044. [Epub ahead of print]

498.	Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic 18F-FDG PET
	Sarkar S¹, Corwin MT², Olson KA³, Stewart SL⁴, Liu CH¹, Badawi RD², Wang G². AJR Am J Roentgenol. 2019 Jan 23:1-9. doi: 10.2214/AJR.18.20012. [Epub ahead of print]

499.	Pathophysiology of Nonalcoholic Steatohepatitis
	McCullough AJ¹. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-S29. doi: 10.1097/01.mcg.0000168645.86658.22.

500.	The antioxidant effects of Hydroxytyrosol and Vitamin E on pediatric NAFLD, in a clinical trial: a new treatment?
	Nobili V¹, Alisi A², Mosca A³, Crudele A⁴, Zaffina S⁵, Denaro M⁶, Smeriglio A⁷, Trombetta D⁸. Antioxid Redox Signal. 2018 Dec 27. doi: 10.1089/ars.2018.7704. [Epub ahead of print]

501.

Prevalence and Risk Factors if Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

Pelusi S¹, Cespiati A², Rametta R³, Pennisi G⁴, Mannisto V⁵, Rosso C⁶, Baselli G¹, Dongiovanni P³, Fracanzani AL², Badiali S⁷, Maggioni M⁸, Craxi A⁴, Fargion S², Prati D⁹, Nobili V¹⁰, Bugianesi E⁶, Romeo S¹¹, Pihlajamaki J⁵, Petta S⁴, Valenti L¹². Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30074-6. doi: 10.1016/j.cgh.2019.01.027. [Epub ahead of print]

502.	Imbalance in gut microbes from babies born to obese mothers increases gut permeability and myeloid cell adaptations that provoke obesity and NAFLD
	Soderborg TK¹, Friedman JE¹,²,³. Microb Cell. 2018 Dec 19;6(1):102-104. doi: 10.15698/mic2019.01.666.

503.	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis
	Mantovani A¹, Gatti D², Zoppini G¹, Lippi G³, Bonora E¹, Byrne CD⁴,⁵, Nobili V⁶,⁷, Targher G¹. Hepatology. 2019 Jan 31. doi: 10.1002/hep.30538. [Epub ahead of print]

504.	Non-Invasive Assessment of Liver Disease in Patients with NAFLD
	Castera L¹, Friedrich-Rust M², Loomba R³. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30051-4. doi: 10.1053/j.gastro.2018.12.036. [Epub ahead of print]

505.	Perinatal Nutritional Reprogramming of the Epigenome Promotes Subsequent Development of Nonalcoholic Steatohepatitis
	Gutierrez Sanchez LH¹, Tomita K², Guo Q², Furuta K², Alhuwaish H², Hirsova P²,³, Baheti S⁴, Alver B⁵, Hlady R⁵, Robertson KD⁵, Ibrahim SH¹,². Hepatol Commun. 2018 Oct 1;2(12):1493-1512. doi: 10.1002/hep4.1265. eCollection 2018 Dec.

506.	Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients
	Uehara D¹,², Seki Y³, Kakizaki S⁴, Horiguchi N², Tojima H², Yamazaki Y², Sato K², Yamada M¹,⁵, Uraoka T², Kasama K³. Obes Surg. 2018 Dec 12. doi: 10.1007/s11695-018-03641-2. [Epub ahead of print]

507.	Incidence of Recurrent NASH-Related Allograft Cirrhosis
	Kakar S¹, Dugum M², Cabello R¹, Humar A³, Ahmad J⁴, Malik SM⁵. Dig Dis Sci. 2018 Dec 17. doi: 10.1007/s10620-018-5413-9. [Epub ahead of print]

508.	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
	Rinella ME¹, Trotter JF², Abdelmalek MF³, Paredes AH⁴, Connelly MA⁵, Jaros MJ⁶, Ling L⁷, Rossi SJ⁷, DePaoli AM⁷, Harrison SA⁸. J Hepatol. 2018 Dec 8. pii: S0168-8278(18)32615-1. doi: 10.1016/j.jhep.2018.11.032. [Epub ahead of print]

509.	Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease
	Sharpton SR¹, Yong GJM¹, Terrault NA¹, Lynch SV¹. Hepatol Commun. 2018 Dec 3;3(1):29-43. doi: 10.1002/hep4.1284. eCollection 2019 Jan.

510.	The role of the microbiome in NAFLD and NASH
	Kolodziejczyk AA¹, Zheng D¹,², Shibolet O³,⁴, Elinav E⁵. EMBO Mol Med. 2018 Dec 27. pii: e9302. doi: 10.15252/emmm.201809302. [Epub ahead of print]

511.	Interventions to improve liver enzyme screening testing in obese patients aged <18 years in a public hospital, Chicago, IL, 2017-2018
	Ward M¹, Nguyen P¹, Akintorin S², Arcia R¹, Soyemi K¹,³. Pediatric Health Med Ther. 2018 Dec 19;10:1-4. doi: 10.2147/PHMT.S183900. eCollection 2019.

512.	Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
	Arshad T¹, Golabi P², Paik J², Mishra A¹, Younossi ZM¹,². Hepatol Commun. 2018 Nov 27;3(1):74-83. doi: 10.1002/hep4.1285. eCollection 2019 Jan.

513.	Predicting outcomes of liver transplantation in patients with NASH: pre-transplant renal function is key
	Piano S¹, Tonon M¹, Angeli P¹. Liver Transpl. 2019 Jan 18. doi: 10.1002/lt.25413. [Epub ahead of print]

514.	NASH in Lean Individuals
	Younes R¹, Bugianesi E¹. Semin Liver Dis. 2019 Jan 17. doi: 10.1055/s-0038-1677517. [Epub ahead of print]

515.	Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
	Brar G¹, Tsukamoto H²,³. J Gastroenterol. 2019 Jan 14. doi: 10.1007/s00535-018-01542-w. [Epub ahead of print]

516.	Validation of Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis in Patients with Biopsy-Proven Non-alcoholic Steatohepatitis
	Younossi ZM¹, Stepanova M², Younossi I², Racila A³. Clin Gastroenterol Hepatol. 2019 Jan 10. pii: S1542-3565(19)30021-7. doi: 10.1016/j.cgh.2019.01.001. [Epub ahead of print]

517.	Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study
	Pfirrmann D¹, Huber Y², Schattenberg JM², Simon P¹. J Med Internet Res. 2019 Jan 2;21(1):e11250. doi: 10.2196/11250.

518.	Predictors of De NovoNonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis
	Galvin Z¹,², Rajakumar R¹, Chen E¹, Adeyi O¹,², Selzner M¹,³, Grant D¹,³, Sapisochin G¹,³, Greig P¹,³, Cattral M¹,³, McGilvray I¹,³, Ghanekar A¹,³, Selzner N¹,², Lilly L¹,², Patel K¹,², Bhat M¹,². Liver Transpl. 2019 Jan;25(1):56-67. doi: 10.1002/lt.25338.

519.	A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?
	van Welzen BJ¹, Mudrikova T², El Idrissi A², Hoepelman AIM², Arends JE². Infect Dis Ther. 2019 Jan 3. doi: 10.1007/s40121-018-0229-7. [Epub ahead of print]

520.	Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease
	Kovalic AJ¹, Banerjee P², Tran QT³, Singal AK⁴, Satapathy SK⁵. J Clin Exp Hepatol. 2018 Dec;8(4):390-402. doi: 10.1016/j.jceh.2018.04.001. Epub 2018 Apr 25.

521.	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
	Patel SS¹, Siddiqui MS². Drugs. 2018 Dec 26. doi: 10.1007/s40265-018-1040-1. [Epub ahead of print]

522.	The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality from Cirrhosis
	Cotter TG¹, Charlton M¹. Hepatology. 2018 Dec 20. doi: 10.1002/hep.30408. [Epub ahead of print]

523.	Association of Parity in Patients with Chronic Liver Disease
	Golabi P¹, Fazel S¹, Otgonsuren M¹, Escheik C¹, Sayiner M¹, Younossi ZM¹. Ann Hepatol. 2018 Oct 16;17(6):1035-1041. doi: 10.5604/01.3001.0012.7204.

524.	Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies
	Prat LI¹,², Roccarina D¹, Lever R³, Lombardi R¹, Rodger A³,⁴, Hall A¹,⁵, Luong TV¹, Bhagani S³, Tsochatzis E¹. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001942. [Epub ahead of print]

525.

Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study

Lemoine M¹, Assoumou L², De Wit S³, Girard PM⁴, Valantin MA⁵, Katlama C⁵, Necsoi C³, Campa P⁴, Huefner AD⁶, Schulze Zur Wiesch J⁶, Rougier H⁴, Bastard JP⁷,⁸, Stocker H⁹, Mauss S¹⁰, Serfaty L¹¹, Ratziu V¹², Menu Y¹³, Schlue J¹⁴, Behrens G¹⁵, Bedossa P¹⁶, Capeau J⁸, Ingiliz P¹⁷, Costagliola D². J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001936. [Epub ahead of print]

526.	Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity
	Yu EL¹, Golshan S², Harlow KE¹, Angeles JE³, Durelle J³, Goyal NP¹, Newton KP¹, Sawh MC¹, Hooker J⁴, Sy EZ⁴, Middleton MS⁴, Sirlin CB⁴, Schwimmer JB⁵. J Pediatr. 2018 Dec 14. pii: S0022-3476(18)31609-3. doi: 10.1016/j.jpeds.2018.11.021. [Epub ahead of print]

527.	Prior Bariatric Surgery in Liver Transplant Candidates: Unforeseen Consequences?
	Sharpton SR¹, Terrault NA¹. Liver Transpl. 2018 Dec 26. doi: 10.1002/lt.25401. [Epub ahead of print]

528.	Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH
	Lombardo J¹, Broadwater D², Collins R², Cebe K², Brady R², Harrison S³. Hum Pathol. 2018 Dec 28. pii: S0046-8177(18)30484-2. doi: 10.1016/j.humpath.2018.11.029. [Epub ahead of print]

529.	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand
	Calzadilla-Bertot L¹, Jeffrey GP¹,², Jacques B², McCaughan G³, Crawford M³, Angus P⁴, Jones R⁴, Gane E⁵, Munn S⁵, Macdonald G⁶, Fawcett J⁶, Wigg A⁷, Chen J⁷, Fink M⁸, Adams LA¹,². Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361.

530.	Consumption of decaffeinated coffee protects against the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function
	Brandt A¹, Nier A¹, Jin CJ², Baumann A¹, Jung F¹, Ribas V³, García-Ruiz C⁴, Fernández-Checa JC⁴, Bergheim I⁵. Redox Biol. 2018 Dec 23;21:101092. doi: 10.1016/j.redox.2018.101092. [Epub ahead of print]

531.	Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
	Ahmed Z¹, Ren J², Gonzalez A³, Ahmed U⁴, Walayat S⁴, Martin DK⁵, Moole H⁴, Yong S⁶, Koppe S⁷, Dhillon S⁵. Hepat Med. 2018 Oct 24;10:133-138. doi: 10.2147/HMER.S160616. eCollection 2018.

532.	Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease
	Alfani R¹,², Vassallo E³,⁴, De Anseris AG⁵, Nazzaro L⁶, D'Acunzo I⁷,⁸, Porfito C⁹,¹⁰, Mandato C¹¹, Vajro P¹²,¹³,¹⁴,¹⁵. Children (Basel). 2018 Dec 13;5(12). pii: E169. doi: 10.3390/children5120169.

533.	Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
	Spooner MH¹, Jump DB. Curr Opin Clin Nutr Metab Care. 2018 Dec 28. doi: 10.1097/MCO.0000000000000539. [Epub ahead of print]

534.	New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fattyliver disease
	Barbara M¹, Scott A², Alkhouri N¹,².

535.	Prevalence and Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) among Asian American Adults in the United States
	Golabi P¹, Paik J¹, Hwang JP², Wang S³, Lee HM⁴, Younossi ZM¹,⁵. Liver Int. 2018 Dec 29. doi: 10.1111/liv.14038. [Epub ahead of print]

536.	Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis
	Whitsett M¹, Wilcox J², Yang A³, Zhao L³, Rinella M⁴, VanWagner LB³,⁴. Liver Int. 2018 Dec 7. doi: 10.1111/liv.14018. [Epub ahead of print]

537.

Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK

Williams R¹, Alexander G², Aspinall R³, Batterham R⁴, Bhala N⁵, Bosanquet N⁶, Severi K⁷, Burton A⁸, Burton R⁹, Cramp ME¹⁰, Day N¹¹, Dhawan A¹², Dillon J¹³, Drummond C¹⁴, Dyson J¹⁵, Ferguson J¹⁶, Foster GR¹⁷, Gilmore I¹⁸, Greenberg J¹⁹, Henn C⁹, Hudson M¹⁵, Jarvis H²⁰, Kelly D²¹, Mann J²², McDougall N²³, McKee M²⁴, Moriarty K²⁵, Morling J²⁶, Newsome P²⁷, O'Grady J¹², Rolfe L⁹, Rice P²⁸, Rutter H²⁹, Sheron N³⁰, Thorburn D³¹, Verne J⁹, Vohra J³², Wass J³³, Yeoman A³⁴. Lancet. 2018 Dec 1;392(10162):2398-2412. doi: 10.1016/S0140-6736(18)32561-3. Epub 2018 Nov 22.

538.	Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research
	Gottlieb A, Mosthael W, Sowa JP, Canbay A. Digestion. 2018 Dec 7:1-7. doi: 10.1159/000493259. [Epub ahead of print]

539.	Macrophages in the Aging Liver and Age-Related Liver Disease
	Stahl EC¹, Haschak MJ¹, Popovic B¹, Brown BN¹. Front Immunol. 2018 Nov 30;9:2795. doi: 10.3389/fimmu.2018.02795. eCollection 2018.

540.	Modulation of Insulin Resistance in NAFLD
	Khan R¹,²,³, Bril F⁴,⁵, Cusi K⁴,⁵, Newsome PN¹,²,³. Hepatology. 2018 Dec 16. doi: 10.1002/hep.30429. [Epub ahead of print]

541.	A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease
	Danford CJ¹, Connelly MA², Shalaurova I², Kim M³, Herman MA⁴, Nasser I⁵, Otvos JD², Afdhal NH¹, Jiang ZG¹, Lai M¹. Hepatol Commun. 2018 Nov 1;2(12):1467-1478. doi: 10.1002/hep4.1267. eCollection 2018 Dec.

542.	Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
	Vilar-Gomez E¹, Vuppalanchi R¹, Gawrieh S¹, Ghabril M¹, Saxena R², Cummings OW², Chalasani N¹. Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368. [Epub ahead of print]

543.	Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study
	Cook NS¹, Nagar SH², Jain A², Balp MM³, Mayländer M⁴, Weiss O⁴, Chatterjee S². Adv Ther. 2018 Dec 13. doi: 10.1007/s12325-018-0856-0. [Epub ahead of print]

544.	Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials
	Brunt EM¹, Kleiner DE², Wilson LA³, Sanyal AJ⁴, BA⁵; Neuschwander-Tetri Hepatology. NASH CRN. 2018 Dec 14. doi:10.1002/hep.30418. [Epub ahead of print]

545.	Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects
	Newfield RS¹, Graves CL¹, Newbury RO², Schwimmer JB³, Proudfoot JA⁴, Say DS⁵, Feldstein AE³. Pediatr Diabetes. 2018 Nov 22. doi: 10.1111/pedi.12798. [Epub ahead of print]

546.	Lean non-alcoholic fatty liver disease
	Wang AY¹, Dhaliwal J², Mouzaki M³. Clin Nutr. 2018 Aug 17. pii: S0261-5614(18)31350-5. doi: 10.1016/j.clnu.2018.08.008. [Epub ahead of print]

547.	Liver Fat is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study
	Fricker ZP¹, Pedley A², Massaro JM³, Vasan RS⁴, Hoffmann U⁵, Benjamin EJ⁶, Long MT⁷. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31280-1. doi: 10.1016/j.cgh.2018.11.037. [Epub ahead of print]

548.	Care of Patients Following Cure of Hepatitis C Virus Infection
	Terrault NA¹. Gastroenterol Hepatol (N Y). 2018 Nov;14(11):629-634.

549.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease

Younossi ZM¹, Stepanova M², Ong J³, Yilmaz Y⁴, Duseja A⁵, Eguchi Y⁶, El Kassas M⁷, Castellanos-Fernandez M⁸, George J⁹, Jacobson IM¹⁰, Bugianesi E¹¹, Wai-Sun Wong V¹², Arrese M¹³, de Ledinghen V¹⁴, Romero-Gomez M¹⁵, Mendez-Sanchez N¹⁶, Ahmed A¹⁷, Wong R¹⁸, Papatheodoridis G¹⁹, Serfaty L²⁰, Younossi I², Nader F², Ziayee M², Afendy A²; Global NASH Council. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31276-X. doi: 10.1016/j.cgh.2018.11.033. [Epub ahead of print]

550.	Non-Alcoholic Fatty Liver Disease-A Global Public Health Perspective
	Younossi ZM¹. J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32517-0. doi: 10.1016/j.jhep.2018.10.033. [Epub ahead of print]

551.	Association between vitamin D levels and nonalcoholic fatty liver disease: potential confounding variables
	Pacifico L¹, Osborn JF², Bonci E³, Pierimarchi P⁴, Chiesa C⁴. Mini Rev Med Chem. 2018 Oct 25. doi: 10.2174/1389557518666181025153712. [Epub ahead of print]

552.	Steatosis in Liver Transplantation: Current Limitations and Future Strategies
	Linares I¹,²,³, Hamar M¹,⁴, Selzner N¹, Selzner M¹. Transplantation. 2018 Nov 9. doi: 10.1097/TP.0000000000002466. [Epub ahead of print]

553.	Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study
	Adams LC¹, Lübbe F¹, Bressem K¹, Wagner M¹, Hamm B¹, Makowski MR¹. PLoS One. 2018 Nov 14;13(11):e0206450. doi: 10.1371/journal.pone.0206450. eCollection 2018.

554.	The Future of Nonalcoholic Fatty Liver Disease Treatment
	Mazhar K¹. Med Clin North Am. 2019 Jan;103(1):57-69. doi: 10.1016/j.mcna.2018.08.005. Epub 2018 Nov 1.

555.	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
	Shiffman M¹, Freilich B², Vuppalanchi R³, Watt K⁴, Chan JL⁵, Spada A⁵, Hagerty DT⁵, Schiff E⁶. Aliment Pharmacol Ther. 2019 Jan;49(1):64-73. doi: 10.1111/apt.15030. Epub 2018 Nov 14.

556.	Non-alcoholic fatty liver disease and colorectal cancer survival
	Wu K¹, Zhai MZ², Weltzien EK³, Cespedes Feliciano EM³, Meyerhardt JA⁴, Giovannucci E⁵,⁶, Caan BJ³. Cancer Causes Control. 2018 Nov 15. doi: 10.1007/s10552-018-1095-z. [Epub ahead of print]

557.	Patient-reported outcomes for NAFLD/NASH: rational for expanded use
	Carrieri P¹, Duracinsky M²,³,⁴, Marcellin F¹, Lazarus JV⁵. Hepatology. 2018 Nov 25. doi: 10.1002/hep.30356. [Epub ahead of print]

558.	Non-alcoholic Steatohepatitis (NASH) Drug Discovery - Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development
	Dash RP¹, Babu RJ, Srinivas NR. J Pharm Pharm Sci. 2018;21(1):481-495. doi: 10.18433/jpps30022.

559.	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
	Sayiner M¹, Lam B², Golabi P², Younossi ZM³. Therap Adv Gastroenterol. 2018 Nov 15;11:1756284818811508. doi: 10.1177/1756284818811508. eCollection 2018.

560.	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale
	Mann JP¹, Vreugdenhil A², Socha P³, Ja?czyk W³, Baumann U⁴, Rajwal S⁵, Casswall T⁶, Marcus C⁷, van Mourik I⁸, O'Rahilly S⁹, Savage DB⁹, Noble-Jamieson G¹⁰, Lacaille F¹¹, Dabbas M¹¹, Dubern B¹², Kelly DA⁸, Nobili V¹³, Anstee QM¹⁴. Contemp Clin Trials. 2018 Dec;75:67-71. doi: 10.1016/j.cct.2018.11.003. Epub 2018 Nov 5.

561.	Clinical workup of fatty liver for the primary care provider
	Jensen T¹, Wieland A², Cree-Green M³, Nadeau K³, Sullivan S⁴. Postgrad Med. 2018 Nov 29:1-12. doi: 10.1080/00325481.2019.1546532. [Epub ahead of print]

562.	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
	Glass O¹, Henao R²,³, Patel K⁴, Guy CD⁵, Gruss HJ⁶, Syn WK⁷,⁸, Moylan CA⁹, Streilein R¹⁰, Hall R¹⁰, Mae Diehl A⁹, Abdelmalek MF⁹. Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov.

563.	Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design
	Rudolph B¹, Bjorklund N², Ovchinsky N³, Kogan-Liberman D³, Perez A³, Liszewski M⁴, Levin TL⁴, Ewart M⁴, Liu Q⁴, Xue X⁵, Viswanathan S⁵, Strickler HD⁵. Contemp Clin Trials. 2018 Dec;75:51-58. doi: 10.1016/j.cct.2018.10.012. Epub 2018 Oct 27.

564.	Nonalcoholic Fatty Liver Disease
	Wang XJ¹, Malhi H¹. Ann Intern Med. 2018 Nov 6;169(9):ITC65-ITC80. doi: 10.7326/AITC201811060.

565.	Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease
	Kwon I¹, Jun DW², Moon JH³. Gut Liver. 2018 Oct 30. doi: 10.5009/gnl18175. [Epub ahead of print]

566.	Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
	Grohmann M¹, Wiede F², Dodd GT¹, Gurzov EN³, Ooi GJ⁴, Butt T¹, Rasmiena AA⁵, Kaur S¹, Gulati T⁵, Goh PK², Treloar AE⁵, Archer S⁶, Brown WA⁴, Muller M⁷, Watt MJ³, Ohara O⁸, McLean CA⁹, Tiganis T¹⁰. Cell. 2018 Nov 15;175(5):1289-1306.e20. doi: 10.1016/j.cell.2018.09.053. Epub 2018 Oct 25.

567.	Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
	Finck BN¹. Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024.

568.	BET Inhibition Improves NASH and Liver Fibrosis
	Middleton SA¹, Rajpal N¹, Cutler L², Mander P³, Rioja I³, Prinjha RK³, Rajpal D¹, Agarwal P¹, Kumar V⁴. Sci Rep. 2018 Nov 22;8(1):17257. doi: 10.1038/s41598-018-35653-4.

569.	Validation of Serum Test for Advanced Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis
	Loomba R¹, Jain A², Diehl AM³, Guy CD⁴, Portenier D⁵, Sudan R⁵, Singh S⁶, Faulkner C⁶, Richards L⁶, Hester KD², Okada L², Li XJ², Mimms L², Abdelmalek MF⁷. Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31247-3. doi: 10.1016/j.cgh.2018.11.004. [Epub ahead of print]

570.	Management of Recurrent and De Novo NAFLD/NASH after Liver Transplantation
	Germani G¹, Laryea M², Rubbia-Brandt L³, Egawa H⁴, Burra P¹, O'Grady J⁵, Watt KD⁶. Transplantation. 2018 Oct 17. doi: 10.1097/TP.0000000000002485. [Epub ahead of print]

571.	Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
	Sundaram V¹, Morgan TR². Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008.

572.	Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis
	Morrison AE¹, Zaccardi F¹,², Khunti K¹,², Davies MJ¹. Liver Int. 2018 Oct 25. doi: 10.1111/liv.13994. [Epub ahead of print]

573.	Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis
	Wang B¹, Li W¹, Fang H¹, Zhou H¹. Mol Med Rep. 2018 Nov 2. doi: 10.3892/mmr.2018.9619. [Epub ahead of print]

574.	Non-alcoholic fatty liver disease: a narrative review of genetics
	Danford CJ¹, Yao Z², Jiang ZG¹. J Biomed Res. 2018 Oct 24. doi: 10.7555/JBR.32.20180045. [Epub ahead of print]

575.	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
	Sao R¹, Aronow WS¹. Arch Med Sci. 2018 Oct;14(6):1233-1244. doi: 10.5114/aoms.2017.68821. Epub 2017 Jul 5.

576.	A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
	Kumar DP¹, Santhekadur PK¹,², Seneshaw M¹, Mirshahi F¹, Tuculescu CU³, Sanyal AJ¹,². Hepatology. 2018 Nov 5. doi: 10.1002/hep.30346. [Epub ahead of print]

577.	Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH
	Chalasani N¹, Abdelmalek MF², Loomba R³, Kowdley KV⁴, McCullough AJ⁵, Dasarathy S⁵, Neuschwander-Tetri BA⁶, Terrault N⁷, Ferguson B, Shringarpure R⁸, Shapiro D⁸, Sanyal AJ⁹. Liver Int. 2018 Sep 25. doi: 10.1111/liv.13974. [Epub ahead of print]

578.	Tie-ing up angiogenesis to treat NASH
	Davidson NO¹. Hepatology. 2018 Oct 16. doi: 10.1002/hep.30318. [Epub ahead of print]

579.	Longitudinal analysis of risk of Non-Alcoholic Fatty Liver Disease (NAFLD) in adulthood
	Cuthbertson DJ¹, Brown E¹, Koskinen J²,³, Magnussen CG²,⁴, Hutri-Kähönen N⁵, Sabin M⁶,⁷, Tossavainen P⁸, Jokinen E⁹, Laitinen T¹⁰, Viikari J¹¹,¹², Raitakari OT², Juonala M⁶,¹¹,¹². Liver Int. 2018 Oct 22. doi: 10.1111/liv.13993. [Epub ahead of print]

580.	Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications
	Henry RK¹. Metab Syndr Relat Disord. 2018 Oct 20. doi: 10.1089/met.2018.0056. [Epub ahead of print]

581.	NAFLD and liver transplantation in children - Working group report from the ILTS single topic conference on NAFLD
	Cananzi M¹, Vajro P², Rela M³, Dhawan A⁴. Transplantation. 2018 Oct 31. doi: 10.1097/TP.0000000000002490. [Epub ahead of print]

582.	Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment
	Braun HA¹, Faasse SA², Vos MB². Gastroenterol Clin North Am. 2018 Dec;47(4):949-968. doi: 10.1016/j.gtc.2018.07.016. Epub 2018 Sep 28.

583.	Chronic Kidney Disease is Independently Associated with Increased Mortality in Patients with Non-alcoholic Fatty Liver Disease
	Paik J¹, Golabi P¹, Younoszai Z¹, Mishra A², Trimble G², Younossi ZM¹. Liver Int. 2018 Oct 22. doi: 10.1111/liv.13992. [Epub ahead of print]

584.	Treatment of NASH with Gastric Bypass
	Jirapinyo P¹,², Thompson CC³,⁴. Curr Gastroenterol Rep. 2018 Sep 22;20(10):49. doi: 10.1007/s11894-018-0653-6.

585.	Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
	Pickett-Blakely O¹, Young K¹, Carr RM¹. Cell Mol Gastroenterol Hepatol. 2018 Aug 23;6(4):451-462. doi: 10.1016/j.jcmgh.2018.07.004. eCollection 2018.

586.	The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD
	Carter A¹, Brackley SM², Gao J³, Mann JP⁴. J Hepatol. 2018 Oct 10. pii: S0168-8278(18)32453-X. doi: 10.1016/j.jhep.2018.09.028. [Epub ahead of print]

587.	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
	Munteanu M¹,²,³, Pais R²,³, Peta V¹, Deckmyn O¹, Moussalli J², Ngo Y¹, Rudler M², Lebray P², Charlotte F², Thibault V², Lucidarme O²,³, Ngo A²,³, Imbert-Bismut F², Housset C³, Thabut D²,³, Ratziu V²,³, Poynard T²,³; FibroFrance Group. Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17.

588.	Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging
	Koch LK¹, Yeh MM². Ann Diagn Pathol. 2018 Sep 27;37:83-90. doi: 10.1016/j.anndiagpath.2018.09.009. [Epub ahead of print]

589.	Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA
	Nguyen MH¹, Nguyen AL², Park H³, Nguyen P⁴, Sheen E⁴, Kim YA⁴. Dig Dis Sci. 2018 Oct 16. doi: 10.1007/s10620-018-5326-7. [Epub ahead of print]

590.	The future R&D landscape in non-alcoholic steatohepatitis (NASH)
	Black D¹, Brockbank S², Cruwys S³, Goldenstein K², Hein P², Humphries B⁴. Drug Discov Today. 2018 Oct 3. pii: S1359-6446(18)30119-3. doi: 10.1016/j.drudis.2018.09.020. [Epub ahead of print]

591.	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
	Younossi ZM¹, Marchesini G², Pinto-Cortez H³, Petta S. Transplantation. 2018 Oct 17. doi: 10.1097/TP.0000000000002484. [Epub ahead of print]

592.	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers
	Mazzotti A¹, Caletti MT¹, Brodosi L¹, Di Domizio S¹, Forchielli ML¹, Petta S², Bugianesi E³, Bianchi G¹, Marchesini G⁴. J Hepatol. 2018 Nov;69(5):1155-1163. doi: 10.1016/j.jhep.2018.07.013. Epub 2018 Oct 2.

593.	Predictors of Nonalcoholic Steatohepatitis and Significant Fibrosis in Non-Obese Nonalcoholic Fatty Liver Disease
	Kim D¹, Kim W², Joo SK², Kim JH³, Harrison SA⁴, Younossi ZM⁵, Ahmed A¹. Liver Int. 2018 Oct 8. doi: 10.1111/liv.13983. [Epub ahead of print]

594.	Liver fat scores predict liver disease mortality in the United States population.
	Unalp-Arida A¹, Ruhl CE². Aliment Pharmacol Ther. 2018 Nov;48(9):1003-1016. doi: 10.1111/apt.14967. Epub 2018 Sep 18

595.	Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease
	Elbel EE¹, Lavine JE¹, Downes M², Van Natta M³, Yu R², Schwimmer JB⁴, Behling C⁴, Brunt EM⁵, Tonascia J³, Evans R². Hepatol Commun. 2018 Sep 27;2(10):1213-1226. doi: 10.1002/hep4.1232. eCollection 2018 Oct.

596.	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
	Shahab O¹, Biswas R¹, Paik J², Bush H², Golabi P², Younossi ZM¹,². Hepatol Commun. 2018 Sep 24;2(10):1227-1234. doi: 10.1002/hep4.1241. eCollection 2018 Oct.

597.	NASH: The Emerging Most Common Form of Chronic Liver Disease
	Tesfay M¹, Goldkamp WJ², Neuschwander-Tetri BA³. Mo Med. 2018 May-Jun;115(3):225-229.

598.	Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis
	Rosenblatt R¹, Mehta A², Snell D², Hissong E³, Kierans AS⁴, Kumar S⁵. Dig Dis Sci. 2018 Sep 29. doi: 10.1007/s10620-018-5295-x. [Epub ahead of print]

599.	Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
	Dibba P¹, Li AA², Perumpail BJ³, John N⁴, Sallam S⁵, Shah ND⁶, Kwong W⁷, Cholankeril G⁸, Kim D⁹, Ahmed A¹⁰. Diseases. 2018 Sep 19;6(3). pii: E83. doi: 10.3390/diseases6030083.

600.	Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study
	Ooi GJ¹,², Burton PR³,⁴, Bayliss J⁵,⁶, Raajendiran A⁵,⁶, Earnest A⁷, Laurie C³,⁴, Kemp WW⁸, McLean CA⁹, Roberts SK⁸, Watt MJ⁵,⁶, Brown WA³,⁴. Obes Surg. 2018 Sep 18. doi: 10.1007/s11695-018-3479-2. [Epub ahead of print]

601.	Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
	Connolly JJ¹, Ooka K², Lim JK³. J Clin Transl Hepatol. 2018 Sep 28;6(3):264-275. doi: 10.14218/JCTH.2017.00056. Epub 2018 Jun 28.

602.	When to Initiate Weight Loss Medications in the NAFLD Population
	Yoo ER¹, Sallam S², Perumpail BJ³, Iqbal U⁴, Shah ND⁵, Kwong W⁶, Cholankeril G⁷, Kim D⁸, Ahmed A⁹. Diseases. 2018 Sep 30;6(4). pii: E91. doi: 10.3390/diseases6040091.

603.	Obesity and nonalcoholic fatty liver disease: current perspectives
	Sarwar R¹, Pierce N², Koppe S³. Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542. doi: 10.2147/DMSO.S146339. eCollection 2018.

604.	Nonalcoholic Liver Disease in Children and Adolescents
	Smith SK¹, Perito ER². Clin Liver Dis. 2018 Nov;22(4):723-733. doi: 10.1016/j.cld.2018.07.001. Epub 2018 Aug 22.

605.	Factors Associated with Histologic Response in Adult Patients with Nonalcoholic Steatohepatitis
	Loomba R¹, Sanyal AJ², Kowdley KV³, Terrault N⁴, Chalasani NP⁵, Abdelmalek MF⁶, McCullough AJ⁷, Shringarpure R⁸, Ferguson B⁸, Lee L⁸, Chen J⁸, Liberman A⁸, Shapiro D⁸, Neuschwander-Tetri BA⁹. Gastroenterology. 2018 Sep 14. pii: S0016-5085(18)34977-1. doi: 10.1053/j.gastro.2018.09.021. [Epub ahead of print]

606.	An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease
	Younossi ZM¹,²,³, Karrar A⁴,⁵, Pierobon M⁶, Birerdinc A⁴, Stepanova M⁴,⁵, Abdelatif D⁴,⁷, Younoszai Z⁵, Jeffers T⁵, Felix S⁵, Jeiran K⁶, Hodge A⁶, Zhou W⁶, Monge F⁴,⁷, Alaparthi L⁴,⁷, Chandhoke V⁵,⁶, Goodman ZD⁴,⁷, Petricoin EF⁶. BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.

607.	Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease
	Baker PR 2nd¹, Friedman JE²,³,⁴. J Clin Invest. 2018 Aug 31;128(9):3692-3703. doi: 10.1172/JCI120846. Epub 2018 Aug 31.

608.	Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease
	Shah J¹,²,³, Okubote T¹,²,³, Alkhouri N¹,²,³. Gastroenterol Hepatol (N Y). 2018 Jul;14(7):407-414.

609.	C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population
	Atsawarungruangkit A¹, Chenbhanich J¹, Dickstein G¹. World J Gastroenterol. 2018 Aug 28;24(32):3663-3670. doi: 10.3748/wjg.v24.i32.3663.

610.	Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
	Harrison SA¹, Dennis A², Fiore MM², Kelly MD², Kelly CJ², Paredes AH³, Whitehead JM³, Neubauer S¹,², Traber PG⁴, Banerjee R². PLoS One. 2018 Sep 7;13(9):e0203054. doi: 10.1371/journal.pone.0203054. eCollection 2018.

611.	Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States
	Younossi ZM¹,², Tampi R¹, Priyadarshini M¹, Nader F³, Younossi IM³, Racila A¹,³. Hepatology. 2018 Sep 4. doi: 10.1002/hep.30254. [Epub ahead of print]

612.	Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
	Sanyal AJ¹,². BMC Med. 2018 Aug 24;16(1):148. doi: 10.1186/s12916-018-1149-9.

613.	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
	Leoni S¹, Tovoli F², Napoli L², Serio I², Ferri S², Bolondi L². World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361.

614.	Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
	Shetty A¹, Hsu JW¹, Manka PP², Syn WK³,⁴. Dig Dis Sci. 2018 Aug 18. doi: 10.1007/s10620-018-5242-x. [Epub ahead of print]

615.	Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis
	Hooker JC¹, Hamilton G¹, Park CC¹, Liao S¹, Wolfson T², Dehkordy SF¹, Hong CW¹, Mamidipalli A¹, Gamst A², Loomba R³, Sirlin CB⁴. Abdom Radiol (NY). 2018 Aug 20. doi: 10.1007/s00261-018-1745-3. [Epub ahead of print]

616.	Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH)
	Jia Y¹, French B², Tillman B², French S². Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.y

Veterans at Risk: NASH Management Options to Consider

New Advances in the Management of Patients With NASH